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Abstract 
Problem Statement: Coronary artery disease is a leading cause of death in the United States. 
Millions of Americans have some form of cardiovascular disease, including angina.  Angina 
affects quality of life. Sublingual nitroglycerin (SLNTG) is a mainstay of therapy for the self-
management of angina. Literature suggests a discordance exists between guideline 
recommendations and SLNTG prescribing practices.  
Purpose: To identify knowledge, barriers, and current practice of Nurse Practitioners (NPs) in 
primary care and specialty clinics in North Carolina (NC) in the use of SLNTG in the stable 
ischemic heart disease (SIHD) patient.  
Questions: (1) Do NPs in NC practicing in primary care and specialty clinics report an 
understanding of the use of SLNTG for the self-management of angina? (2) Do NPs report an 
understanding of contraindications for the use of SLNTG? (3) Does the understanding and 
utilization of SLNTG in the SIHD patient differ among practice specialties (such as primary care 
compared to cardiology)?  
Methods: This Doctor of Nursing Practice project was a non-experimental, cross-sectional, 
quantitative project using a descriptive survey administered via electronic-mail to a convenience 
sample of 2236 NPs in NC.  
Analysis: Frequency distribution was used to score the respondents correct responses. 
Understanding and utilization of SLNTG among practice specialties was assessed with Chi-
square for independence.  
Significance: Nurse practitioner respondents were less knowledgeable about SLNTG as 
premedication for effort-induced angina; but were aware of correct dosing of SLNTG, use of 
SLNTG with phosphodiesterase inhibitors and when to replace SLNTG.  
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Nurse Practitioner Use of Sublingual Nitroglycerin in Stable Ischemic Heart Disease 
Section I: Introduction 
Introduction to the Problem 
Coronary artery disease (CAD) remains a leading cause of death in the United States 
(US). Based on data from 2010, every day over 2100 people in the US die of cardiovascular 
disease (CVD; which includes myocardial infarction (MI), angina, heart failure (HF), stroke 
(CVA), or congenital cardiovascular (CV) defects). That equates to approximately one person 
every 40 seconds (Go et al., 2014). Approximately one in three Americans have some form of 
CVD; nearly 17 million live with coronary heart disease (CHD), and ten million suffer from 
angina (Fihn, et al., 2012; Go et al., 2014).  
Go and colleagues (2014) estimate the annual direct and indirect costs of CVD and stroke 
at around $315 billion. Hospitalizations account for more than one-half of the direct costs 
associated with ischemic heart disease (Fihn et al., 2012). Despite aggressive use of 
interventional cardiology procedures and antiplatelet medications, many individuals continue to 
experience chronic angina even after an acute coronary event and intervention (Arnold et al., 
2009). Kempf, Buysman, and Brixner’s (2011) study of health utilization costs for the CAD 
patient with and without angina in a managed care environment estimated that patients who have 
CAD with angina utilized many more health resources. Patients who have CAD with angina 
were more likely to visit the emergency department, have more clinic visits, more 
revascularization procedures, and had higher pharmacy costs (Kempf et al., 2011).  “Total 
average CAD-related medical and pharmacy costs for patients with angina were $14,851 versus 
$4449 for patients with CAD without angina, and the average all-cause per-patient cost was 
$28,590 versus $14,334, respectively” (Kempf, et al., 2011, p. 353). By 2030, Go and 
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colleagues’ (2014) estimate that 43.9% of those in the US will have some form of CVD and costs 
will increase substantially, up to $918 billion (based on 2012 dollars, in billions). 
The 2012 American College of Cardiology Foundation (ACCF)/American Heart 
Association (AHA)/American College of Physicians (ACP)/American Association for Thoracic 
Surgery (AATS)/Preventive Cardiovascular Nurses Association (PCNA)/ Society for 
Cardiovascular Angiography and Intervention (SCAI)/ and Society of Thoracic Surgeons (STS) 
Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease 
(Fihn et al., 2012 [referred henceforth as 2012 SIHD Guideline]) is a valuable resource and basis 
for this DNP project. Sublingual nitroglycerin (SLNTG) or nitroglycerin spray is a class 1, level 
of evidence B recommendation for the immediate relief of angina in patients with stable 
ischemic heart disease (SIHD; Fihn et al., 2012). For the purpose of this project, all short-acting 
nitrate formulations were referred to as SLNTG. Several researchers discussed the 
underutilization of SLNTG and knowledge deficits in the use of SLNTG in patients with chronic 
CAD/stable angina and/or SIHD (Fan, Mitchell, & Cooke, 2009; Gallagher, et al., 2010, 2013; 
Walton-Shirley, 2014; Zimmerman, Fass, Katz, Low, & Franklin, 2009). Most studies focused 
on the patients’ knowledge and use of SLNTG, whereas no studies were found on NP, physician 
or physician assistant (PA) knowledge, use, or prescribing practices in the SIHD patient. The 
absence of such evidence was considered the basis for this project exploring NPs’ knowledge, 
barriers, and current use of SLNTG in the SIHD patient population.  
 Additionally, three of the four studies reviewed for this project on the knowledge and use 
of SLNTG in patients were from Australia (Fan, Mitchell, & Cooke, 2009; Gallagher, et al., 
2010, 2013). These authors’ findings about knowledge and use of SLNTG in patients was used 
as part of the foundation for development of the survey tool subsequently used to assess NPs’ 
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knowledge on the use of SLNTG. The 2012 SIHD Guideline was also used as a basis for survey 
tool development.  
Purpose of Project 
The purpose of this Doctor of Nursing Practice (DNP) scholarly project is to identify 
knowledge, barriers, and current practice as reported by NPs practicing in North Carolina (NC) 
in primary care and specialty clinics in the use of SLNTG in the SIHD patient. Clinical project 
questions explored were:   
1. Do NPs in NC practicing in primary care and specialty clinics report an understanding of 
the use of SLNTG for the self-management of angina? 
2. Do NPs report an understanding of contraindications for the use of SLNTG? 
3. Does the understanding and utilization of SLNTG in the SIHD patient differ among 
practice specialties (such as primary care compared with cardiology)?  
Background of Problem of Interest 
Given the burden of heart disease in America, care for the patient with CAD (or SIHD) is 
very common in adult healthcare practices. In 2010, there were over 10 million outpatient office 
visits with the primary diagnosis of CHD (Go et al., 2014). Chest pain or angina are often a 
manifestation of SIHD. Angina affects quality of life (Akyildiz & Ergene, 2014; Beltrame, 
Weekes, Morgan, Travella & Spertus, 2009) and is associated with long-term anxiety, depression 
and impaired physical functioning (Beatty, Spertus, & Whooley, 2014; Jespersen, Abildstrøm, 
Hvelplund & Prescott, 2013). Sublingual nitroglycerin should be considered a mainstay of 
therapy for the self-management of angina based on the 2012 SIHD Guideline (Fihn et al., 2012). 
Literature suggests there is a discordance between guideline recommendations and actual 
practice in prescribing SLNTG to patients with SIHD for the self-management of angina (Fan et 
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al., 2009; Gallagher et al., 2010; Walton-Shirley, 2014; Zimmerman et al., 2009). Based on the 
evidence, patients may misunderstand and inadvertently misuse SLNTG (Gallagher et al, 2010; 
Zimmerman et al., 2009).  This author’s goal was to increase awareness regarding the 
appropriateness of SLNTG in the SIHD patient and encouraged its use by NPs caring for the 
SIHD patient population according to the standard of care. 
Significance of Problem 
 Although this project focused on NP SLNTG prescribing practice and barriers to 
prescribing SLNTG within the US, this author found no studies superficially addressing 
providers’ (i.e., NP, physician or PA) SLNTG prescribing practice or patterns. However, several 
studies addressed the knowledge and use of SLNTG from the patients’ perspective (Fan et al., 
2009; Gallagher, et al., 2010, 2013; Zimmerman et al., 2009).  One might postulate that 
dangerous misuse or underuse of SLNTG may be avoided by assuring NPs, physicians, and PAs 
are knowledgeable of and effectively communicate the appropriate indications, use and 
contraindications for safe SLNTG use.  
Gallagher (2010) found that 37% (n=53) of patients with CAD were not prescribed 
SLNTG and of those that did receive a prescription for SLNTG, only 43% (n=38) reported 
receiving instruction in its use.  Similarly, 38% (n=233) of patients participating in cardiac 
rehabilitation programs in New York, Michigan and Rhode Island did not have a prescription for 
SLNTG and 23% (n=88) had a prescription for SLNTG that was over one year old (Zimmerman 
et al., 2009).  
Discussion of How Identified Practice Setting Supported Project 
 The practice setting for this project was primary care and specialty clinics (nephrology 
and cardiology) where adult patients are seen with the diagnosis of CAD/SIHD and who may 
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present with symptoms of angina or chest pain. The target audience for this author’s scholarly 
inquiry was NPs in these primary care and specialty clinic settings.  
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Section II: Research Based Evidence 
A thorough literature review in which one describes and appropriately synthesizes the 
literature on a given subject is paramount to delivery of high-quality evidence-based patient care 
(Timmins & McCabe, 2005).  
Review of Literature 
In order to answer the clinical questions pertaining to nurse practitioners’ (NPs) 
knowledge of the use of SLNTG in the SIHD patient, a literature review was conducted using 
electronic databases including Medline via PubMed, Cumulative Index to Nursing and Allied 
Health Literature (CINAHL), Cochrane Database of Systematic Review. The search was limited 
to 2009-2014 and English only articles. Keyword or Medical subject Headings (MeSH) terms 
used included angina, stable angina, nitroglycerin, nitrates (different forms), guidelines, 
evidence-based practice, nurse practitioner, barriers, practice patterns, knowledge, and quality of 
life. Figure A shows a summary of the search.  
Four studies undergirding this project centered on the patients’ perspective and the use of 
SLNTG (Fan et al., 2009; Gallagher, et al., 2010, 2013; Zimmerman et al., 2009). Additionally, 
the 2012 SIHD Guideline were reviewed for specific information on guideline-directed medical 
therapy (GDMT) information on SLNTG in this patient population. Of note, ACC/AHA 
published a new 2014 Focus Update of the Guideline for Diagnosis and Management of Patients 
with SIHD. Although the 2014 ACC/AHA updated guideline was reviewed, the 2012 SIHD 
Guideline was used for foundational evidence to support this author’s project because the 2014 
update provided no relevant information on the use of SLNTG (Fihn et al., 2014). Fihn and 
colleagues (2014) under the GDMT section in the Focus Update elaborated on the use of 
Chelation Therapy and Enhanced External Counterpulsation (EECP) both for the treatment of 
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angina. The 2014 SIHD Focus Update found the use of chelation therapy in cardiac disease 
“highly questionable” (Fihn et al., 2014, p. 1755). As for EECP, reviewed in the 2012 SIHD 
Guideline, the writing group confirmed their findings that EECP might have some benefit in 
patients with refractory angina. The writing group did support the ongoing need for well-design 
randomized controlled trials (RCTs) to further evaluate EECP therapy. Therefore, the 2014 
recommendations are unchanged from 2012 – that “EECP may be considered for relief of 
refractory angina in patients with SIHD” (Fihn et al., 2014, p. 1756).  Information from the 2012 
SIHD Guideline as well as SLNTG knowledge/use issues in patients as identified in the studies 
above (Fan et al., 2009; Gallagher, et al., 2010, 2013; Zimmerman et al., 2009) was used to 
developed the survey used for this project.   
Barriers to Use of SLNTG 
The literature frequently addressed some of the barriers to why evidence-based practice 
(EBP) or clinical guidelines are not easily adopted (Cabana et al., 1999; Fineout-Overholt, 
Melnyk, & Schultz, 2005; Melnyk, Fineout-Overholt, Gallagher-Ford, & Kaplan, 2012; Powell-
Cope, Luther, Neugaard, Vara, & Nelson, 2004). The author found no studies addressing NPs 
barriers to use of SLNTG. Boden and colleagues (2012) in their review of nitrates and their role 
in medical therapy for stable angina provided a brief summary of physician barriers to nitrate 
use. These researchers suggested that physicians were mainly concerned with the development of 
tolerance and/or tachyphylaxis (Boden et al., 2012).  Tachyphylaxis is the “rapid appearance of 
progressive decrease in response to a given dose after repetitive administration” of, for example, 
the SLNTG (MediLexicon International, 2015, para. 4). Physicians in Boden et al.’s report were 
concerned the tachyphylaxis would limit the sustained benefit of the nitroglycerin. Fihn et al. 
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(2012) reported no development of nitrate tolerance with SLNTG; nor did the use of long-acting 
nitrates effect tolerance to the use of SLNTG.  
 In addition, the perception of physicians that medical therapy is less effective than 
invasive procedures such as percutaneous intervention (PCI) is also a barrier to use of SLNTG 
(Boden et al., 2012). Based on their research findings, Boden et al. (2012) posit that many 
patients limit their activity to avoid angina rather than use the SLNTG as indicated to alleviate 
the angina and do not know they can use the SLNTG for symptom prophylaxis.   
Nurse practitioners and physicians alike reported barriers to the use of EBP and/or 
clinical guidelines. These barriers included lack of time in both staying abreast of most recent 
guidelines and implementation of guidelines; lack of education of the actual guidelines; lack of 
organizational support for use of guidelines, and lack of agreement with the guidelines (Cabana 
et al., 1999; Melnyk et al., 2012).  A paucity of literature existed investigating NP knowledge, 
barriers, and current practice specific to the use of SLNTG in the SIHD patient. 
Although not the case in the US, a prescription for SLNTG is not needed in Australia 
(Gallagher et al., 2010). Four knowledge points on the use of SLNTG by patients were 
extrapolated from research in other countries and the 2012 SIHD Guideline to develop the survey 
tool used to assess NP knowledge. The four knowledge points were 1) use of SLNTG as 
premedication for effort-induced angina, 2) SLNTG and the use of phosphodiesterase inhibitors, 
3) dosing intervals for the use of SLNTG, and 4) replacement of SLNTG.  
 In an Australian study by Fan et al. (2009) and two studies by Gallagher et al. (2010 & 
2013), it is important to note that patients in Australia do not have to have a prescription for 
SLNTG. It is available over-the-counter (OTC). “The pharmacist will ask some detail and check 
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that (the patients) are okay” before dispensing (personal communication, R. Gallagher, May 17, 
2015).  
In a non-experimental, retrospective descriptive design, Fan and colleagues (2009) 
surveyed 41 cardiac in-patients in an Australian hospital. The participants were surveyed using a 
modified version of the Sublingual Nitroglycerin Interview Schedule (SNIS) tool. Kimble and 
Kunik (2000) developed the SNIS tool to assess knowledge and use of SLNTG and cardiac-
related quality of life in patients with chronic stable angina. The original tool was 69 items and 
took approximately 30-45 minutes to administer. Content and face validity were established for 
this tool, though the original research by Kimble and Kunik (2000) did not mention if construct 
validity and reliability was assessed. After instrument analysis, Fan et al. used only 58 of the 
original items, removing questions specifically related to the patient’s last episode of chest pain. 
This modified tool was pilot tested with two people similar to the target population to ensure 
appropriate content and phrasing for the Australian setting, No other changes were made (Fan et 
al., 2009).  
Fan et al.’s (2009) findings supported that participants needed to improve their 
knowledge of the use of SLNTG, which would provide the ability to self-manage their angina. 
Only 24% (n=10) of participants knew they could use SLNTG to prevent activity-related chest 
pain. Participants also were not aware of how to transport their SLNTG (i.e. keep in the original 
bottle, away from light, heat, etc.). Fifty-six percent (n=23) reported no ongoing education from 
their healthcare providers on the use of SLNTG, and approximately 48% (n=20) did not know 
the correct dosing sequence for the SLNTG medication.  
In another Australian study, Gallagher and colleagues (2010) recruited 142 patients in 
cardiac rehabilitation (rehab) to survey regarding their use and knowledge of SLNTG. They cited 
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previous estimates of 15-37% of patients with suspected or confirmed diagnosis of coronary 
artery disease (CAD) who had not received a prescription for SLNTG. Of those patients 
previously studied, that had received a prescription for SLNTG, only 30-70% reported receiving 
instructions on the use of SLNTG (Gallagher, et al., 2010). Gallagher et al. (2010) sought to 
ascertain how often SLNTG had been prescribed to those patients in the cardiac rehabilitation 
program, as well as evaluate their knowledge of the use of SLNTG. Inclusion criteria included 
the ability to understand and speak English, recent discharge from the hospital with diagnosis of 
CAD, including acute myocardial infarction (AMI), percutaneous coronary intervention (PCI), 
and/or angina. Excluded were patients who were post coronary artery bypass grafting (CABG) as 
these patients are not typically provided a prescription for SLNTG.  
The questionnaire used by Gallagher et al. (2010) was modified from an existing tool 
developed by Zimmerman (2009). This instrument comprised of 20 questions, addressed 
“prescription, experience, instruction, and the level and accuracy of knowledge of SLNTG” 
(Gallagher et al., 2010, p. 481). Those patients who had a SLNTG prescription were asked an 
additional 20 knowledge questions related to “type of symptoms treated; storage; method, 
sequence, and timing of administration; adverse effects; and safety issues including maximum 
dosage and responses when chest pain symptoms persist” (Gallagher et al., 2010, p. 481). 
Gallagher added four additional questions. Two of the questions were specific to the Australian 
population asking participants if a prescription was needed for SLNTG and/or if they (the 
patient) had ever used another person’s SLNTG.  The remaining two questions Gallagher et al. 
(2010) added were questions inquiring about patients’ knowledge regarding concurrent use of 
SLNTG and nitroglycerin patch or SLNTG and sildenafil (Viagra).  
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Gallagher and colleagues (2010) found that only 43% (n=38) of participants recalled 
receiving any SLNTG education, which most often was provided by the nursing staff (37%, 
n=33). Sixty-seven percent (n=59) knew to keep the SLNTG in its original container and 51% 
(n=45) knew when the SLNTG would expire. Eighty-seven (n=77) to ninety-four percent (n=83) 
of participants reported knowing to stop an activity when chest pain occurred before using the 
SLNTG, to sit down to take the SLNTG and knew how and when to use the SLNTG. 
Conversely, only 70% (n=62) knew the correct sequence of dosing and/or maximum dosage per 
episode (69%, n=61). Of the 12% (n=10) of participants prescribed sildenafil, only 33% (n=3) 
knew that SLNTG should not be used concurrently. Seventy-five percent (n=66) of participants 
knew they could use the SLNTG concurrently with nitroglycerin patches. This study also noted 
that patients lacked knowledge regarding premedicating with SLNTG to prevent CP.  
In 2013, Gallagher and colleagues once again recruited participants from an Australian 
cardiac rehabilitation program to participate in a pre-test, post-test designed study. Participants 
were in phase II of the cardiac rehabilitation program. Inclusion criteria again included patients 
with CAD (either AMI, PCI, or angina) attending cardiac rehabilitation for their initial 
assessment. Patients not prescribed SLNTG were excluded from this study. Sublingual 
nitroglycerin knowledge and use questions were similar to the 2010 study. Following the initial 
assessment of each participant, an educational intervention was done to address the deficits and 
misconceptions around the use of SLNTG identified in the initial assessment. Eighty-six subjects 
completed the study. The post-test portion of the study occurred approximately six to eight 
weeks after the initial educational session. The educational intervention did improve the 
knowledge scores (Gallagher et al., 2013). However, even after the standard educational 
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intervention, only 50% knew the recommended number of SLNTG doses per pain episode 
(n=43) or that SLNTG and nitroglycerin patches could be used together (n=12)  
Zimmerman et al. (2009) recruited participants from nine cardiac rehabilitation programs 
in the New York, Michigan, and Rhode Island areas, surveying 617 participants. For inclusion, 
participants had a diagnosis of angina, myocardial infarction (MI), PCI, CABG or a combination 
of these diagnoses. They found 38% (n=233) of the participants did not have a prescription for 
SLNTG and 23% (n=148) of patients with SLNTG had tablets that were at least one year old.  
Many studies and/or reports have been published on the diagnosis and management of 
CAD, angina, and non-acute coronary syndromes (Agarwal, Mehta, & Merz, 2010; Boden et al., 
2012; Cassar, Holmes, Rihal, & Gersh, 2009; Fihn et al., 2011; Lewis & Davis, 2013; 
Palaniswamy & Aronow, 2011; Tobin, 2010). Most of the aforementioned studies identified 
SLNTG as one mainstay of angina treatment. Lewis and Davis (2013) provided an insightful 
educational review of the management of SIHD reviewing the 2012 SIHD Guideline. They 
discussed the use of SLNTG for the treatment of acute anginal symptoms and reiterated that 
SLNTG can be used prophylactically during exertional activities known to produce angina 
(Lewis & Davis, 2013).  
Concepts and Definitions Used in the Project 
The evidence specific to the use of SLNTG in the 2012 SIHD Guideline provided the 
evidence-based foundation for this DNP project.  In general, the scope of the 2012 SIHD 
Guideline was directed toward adult patients with “stable known, or suspected ischemic heart 
disease, including new-onset chest pain (i.e., those with low-risk unstable angina) or adults with 
stable pain syndromes” (Fihn et al., 2012. p. e50). Patients with ischemic or anginal equivalents, 
such as arm pain with exertion, dyspnea on exertion are included as well.  These equivocal 
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symptoms are especially important to remember when dealing with women (and diabetics), as 
65% of women who present with ischemic findings do so with atypical symptoms (Fihn et al., 
2012). The 2012 SIHD Guideline does not apply to patients who experience chest pain 
symptoms early after revascularization (either PCI or CABG). Early, as defined by the guideline 
writing committee for this population, were patients with recurrent symptoms within six months 
of their revascularization (Fihn et al., 2012).  The 2012 SIHD guideline and this DNP project did 
not include pediatric patients or those with heart transplant and subsequent anginal symptoms.  
Guideline-Directed Medical Therapy (GDMT)  
The term guideline-directed medical therapy (GDMT) was used to represent optimal 
medical therapy as defined by the ACCF/AHA guideline (primarily Class I) recommended 
therapies (Fihn et. al., 2012). The 2012 SIHD Guideline has a thorough review of optimal 
GDMT for SIHD. The purpose of this project was not to review each medication used for the 
management of patients with SIHD, but instead the use of SLNTG as a therapy for self-
management of angina when a patient on GDMT has breakthrough chest pain. The 2012 SIHD 
Guideline suggested that patients are appropriately on anti-platelet medications, beta-blockers, 
calcium channel blockers, angiotensin converting enzyme inhibitors (ACEi), statin therapy, 
ranolazine and/or the combination of these meds; along with lifestyle modifications (diet, 
exercise, smoking cessation, blood pressure and cholesterol control, and glycemic control). 
Sublingual nitroglycerin is used as needed for self-management of breakthrough anginal (or 
chest pain) episodes. Inherent to the successful management of patients with angina and SIHD 
was patients knowing symptoms that are suggestive of unstable angina (worsening chest pain) 
and when to appropriately report to the emergency department for further evaluation.  
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Knowledge 
Knowledge, as defined by the Oxford Dictionary (2015) is the practical, medical, or 
scientific understanding gained through experience and/or education. For the purpose of this 
project, one way knowledge was measured was by the use of scenario based survey questions. In 
this respect, knowledge of the use of SLNTG as described in the 2012 SIHD Guideline was 
evident if the respondent selects the guideline directed answer. As described below, each 
scenario question had one answer that was taken directly from the 2012 SIHD Guideline. For the 
purpose of this survey project, selection of that one particular response equates to knowledge of 
the 2012 SIHD Guideline.  
Barriers  
Barriers as related to the use of SLNTG in the SIHD patient and the use of EBP and 
clinical guidelines was another concept used in this project. Barriers related to both practice in 
using SLNTG when clinically appropriate and behavior barriers relative to evidence-based 
practice or clinical guidelines.  Behavioral barriers included knowledge barriers (lack of 
familiarity to guidelines, too many guidelines and not enough time to stay informed), attitude 
barriers (disagree with guidelines, feel guidelines are too cookbook) and external or 
environmental guidelines (such as patients will not be compliant, organization where employed 
does not support the use of guidelines) are just a few ways barriers relate to this project (Cabana 
et al., 1999).  
Theoretical Framework that Guided the Project 
“Theory guides practice” (McEwen, 2011, p. 79). Roger’s Diffusion of Innovation 
Theory (DOIT) is a theory that attempts to explain how, over time, an idea or product gains 
momentum and spreads (or diffuses) through a specific population or social system (Boston 
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University, 2013).  The desire was that by utilizing the DOIT framework, one can identify areas 
of concern in diffusion of an idea by understanding the underlying principles of the theory and its 
application to a project or idea. The innovation for this DNP project was the use of SLNTG in 
the SIHD patient as outlined in the 2012 SIHD Guideline.  
Diffusion of Innovation Theory 
The framework for the DOIT dates back to at least 1903, with Tarde and his “laws of 
imitation” (as cited in Rogers, 2003, p. 41). Tarde (1903) suggested that adoption of an 
innovation was a social process through interpersonal communication and copying (or imitating) 
someone else’s adoption of the innovation (as cited in Rogers, 2003). Nurses are proficient in the 
use of peer-to-peer learning strategies. However, practical knowledge (gained through 
experience) is not necessarily evidence-based (Proehl & Hoyt, 2012). In 1943, Ryan and Gross 
developed a more focused approach to the DOIT through their results on the use of hybrid-corn 
by Iowa Farmers (Wejnert, 2002). Rogers’ theory was the basis for this project. He posited that 
in the agricultural setting, economics did not affect acceptance (or diffusion of the innovation) 
but rather interpersonal communication based on successful results lead to acceptance of the 
innovation and further diffusion of the practice (Balas, 2012; Rogers, 2003).   
Key Theoretical Concepts 
Rogers (2003) suggested there were four main elements that influence (or facilitate) the 
spread of a new idea (diffusion); “the (1) innovation (2) is communicated through certain 
channels (3) over time (4) among the members of a social system” (p.11). Of importance to this 
author, especially in light of this DNP project, was that the term innovation typically suggested a 
new idea; and the use of SLNTG in the SIHD patient has been a mainstay of therapy for years 
(Fihn et al., 2012; Go et al., 2014, Murrell, 1879). The use of nitroglycerin for angina dates back 
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to at least 1879 (Murrell, 1879). Therefore, the use of SLNTG was not novel. However, the 
chronological novelty of a new discovery or idea as an innovation is less important than if the 
idea seems new to an individual.  “Newness of an innovation need not just involve new 
knowledge” (Rogers, 2003, p. 12). One may know about an innovation (i.e. SLNTG) but not 
have developed an opinion or attitude about it one way or another.  
Facilitating factors. Facilitating factors that affect the rate of adoption include (1) 
relative advantage – does the idea or product have a perceived value over that it supersedes? (2) 
Compatibility – is the idea consistent with the values, experiences, and needs of the potential 
adopters? (3) Complexity – is the innovation easily understood or is it difficult to understand or 
use? (4) Trialability – can the innovation be experimented with to test it out, as it is more likely 
to be adopted if able to try it out first. (5) Observability – to what degree are the results of the 
innovation visible to others? (Greenhalgh, Robert, Bate, Macfarland, and Kyriakidou, 2005; 
Rogers, 2003).  
Barriers. Barriers to acceptance of an innovation can be similar to the facilitating factors 
outlined above. If the innovation lacks value, is not compatible with the value/needs of the 
adopter, too complex or not able to be trialed then may decrease the likelihood of adoption of the 
innovation being proposed (Rogers, 2003).  
Innovation-decision process. The innovation-decision process consists of the five stages 
(1) knowledge, (2) persuasion, (3) decision, (4) implementation, and (5) confirmation. Once an 
individual is aware of the initial knowledge of an innovation or new idea, one begins to form an 
attitude toward the innovation. This knowledge-gathering phase is followed by the decision to 
either adopt or reject the innovation.  Once one decides to adopt an innovation, it is implemented 
and lastly, once implemented the individual will confirm the decision to continue to adopt the 
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innovation or elect to reject if need information is presented. This is the innovation-decision 
process (Rogers, 2003). 
 Knowledge. This is the point when an individual is exposed or learns of an innovation, 
such as use of SLNTG in SIHD, or more specifically, the use of SLNTG as a pre-medication for 
effort-induced angina. Innovation awareness can occur either passively or actively (Rogers, 
2003). Passive awareness-knowledge is one learning of an innovation by accident while active 
awareness-knowledge occurs when one initiates or seeks out the innovation based on a need to 
know. “Change agents may create needs among their clients by pointing out the existence of 
desirable new ideas. Thus knowledge of the existence of an innovation can create a motivation to 
learn more about it and ultimately, to adopt it” (Rogers, 2003, p. 172).  
 Three types of knowledge are related to an innovation: awareness-knowledge, how-to 
knowledge, and principles-knowledge (Rogers 2003).  Awareness-knowledge is the knowledge 
that an innovation exists which may lead the individual to seek out the second or third type 
knowledge (how-to or principle). How-to knowledge is the information needed to use an 
innovation properly. Principle-knowledge is the information needed to understand the principles 
underlying how an innovation works. One can adopt an innovation without principle knowledge, 
but this increases the chance of misusing the innovation or discontinuance of the innovation. 
Rogers (2003) suggests that a change agent should address each of these types of knowledge in 
the innovation-decision process.  
 Persuasion. Persuasion, as used by Rogers (2003) is not the use of intentional means to 
convince someone to adopt an innovation, instead is the individual’s own change in attitude that 
affects if they adopt an innovation or not (Rogers, 2003). The person forms a favorable or 
unfavorable attitude toward an innovation based on actively for him/herself seeking out 
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information about the innovation. Individuals decide what they perceive as credible and decide 
how they will interpret the information received. This perception of the innovation is based on 
the perceived attributes of the innovation based on its relative advantage, compatibility, and 
complexity (Rogers, 2003). The ultimate outcome of persuasion is individuals’ decision at accept 
or reject an innovation based on their attitude toward the innovation.  
 Decision. The decision stage in the innovation-decision process is when one intently 
seeks out activities that lead to adoption or rejection of an innovation. The opportunity to try out 
an innovation helps decreased the uncertainty of an innovation (Rogers, 2003). Just as one is 
likely to adopt an innovation, one can reject an innovation. One example of rejection can be 
simply forgetting about the innovation even after gaining awareness-knowledge or one can reject 
even after deciding to adopt.  
 Implementation. This stage of the innovation-decision process is the actual use of the 
innovation (Rogers, 2003). The innovation is put into practice. The concept of re-invention is 
often noted in the implementation phase. Re-intervention is when one modifies the innovation 
while adopting the innovation to meet their need (Rogers, 2003).  
 Confirmation.  For some, the implementation is the final stage of the innovation-decision 
process. For others, once an innovation is adopted, they may seek out additional information or 
confirmation to reinforce the innovation-decision already made. This additional information may 
lead to rejection of an innovation if conflicting messages are received (Rogers, 2003). There are 
two types of discontinuance described by Rogers (2003). These two types of discontinuance are 
(1) replacement discontinuance and (2) disenchantment discontinuance. Replacement 
discontinuance suggests one decides to reject an idea in order to adopt a better idea that may 
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come along (Rogers, 2003). Disenchantment discontinuance is the dissatisfaction with the 
innovation’s performance (Rogers, 2003).  
Communication channel. One additional concept addressed was the means in which the 
information about an innovation was communicated (Rogers, 2003). For the purpose of this 
project, the means of communication were via mass media (such as journal article) or through 
interpersonal channels (such as podium presentation, poster board presentation or one-on-one 
through dialogue with colleagues, precepting, etc.).  
Application to Project 
 The aim of this project was to assess NP knowledge, barriers, and current practice around 
the use of SLNTG in the SIHD patient. The literature suggests there is a discordance between 
guideline recommendations and actual prescribing of SLNTG. Patients often lack the knowledge 
and understanding of how and when to use SLNTG as well as safety concerns associated with 
the medication (Gallagher et al., 2010; Zimmerman et al., 2009). A survey was developed to 
assess this knowledge and understanding of SLNTG in the SIHD patient.  The survey obtained 
baseline data to identify if there are areas in the NPs’ knowledge and practice that prohibit the 
adoption of SLNTG in the SIHD patient population. Based on this project’s findings, post-
doctoral work can focus on further dissemination of findings in hopes of enhancing the 
knowledge of NPs and other healthcare providers.    
This practitioner’s belief was that most NPs were aware of the use of SLNTG in this 
patient population but failed to prescribe it and educate patients secondary to oversight. 
Nevertheless, once an innovation is introduced, there are five stages in the adoption process. 
Those stages include – knowledge, persuasion, decision, implementation and confirmation 
(Rogers, 2003). It was anticipated that most providers being surveyed have some baseline 
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knowledge regarding the indication for and use of SLNTG. The survey should serve as an 
opportunity to reiterate to NPs information regarding the appropriate use of SLNTG and safety 
issues associated with its use (i.e., principle knowledge). As their awareness is increased, there 
was the expectation that clinicians would adopt the use of SLNTG in the SIHD patient 
population, be more consistent in its use, thereby improving the quality of life of these patients 
with SIHD. See Figure B for illustration of application of theory to this project.  
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CHAPTER III: Methodology 
Overview 
 The methodology section is intended to describe how the project was done with 
relationship to the purpose of the project (Moran, Burson, & Conrad, 2014). A timeline for the 
DNP Program requirements/activities is shown in Appendix C, Figure C.  The purpose of this 
DNP project evaluated 1) do NPs in primary care and specialty clinics report an understanding of 
the use of SLNTG for the self-management of angina; 2) do NPs report an understanding of the 
contraindications for the use of SLNTG; and 3) does the understanding and utilization of SLNTG 
in the SIHD patient differ among practice specialties (such as primary care compared with 
cardiology)?   
Needs Assessment 
 There was no formal needs assessment done related to this DNP Project. There was 
however, a review of the literature to evaluate existing works on the use of SLNTG in SIHD.  
The 2012 SIHD Guideline provides a foundational basis for this project. This author found no 
studies evaluating NP knowledge and use of SLNTG. There were four studies used for this 
project that evaluated patients’ knowledge and use of SLNTG. This author took the information 
on patients’ deficits in their knowledge and use of SLNTG and the 2012 SIHD Guideline 
recommendations on the use of SLNTG and developed a tool to evaluate NP knowledge and use 
of SLNTG in the SIHD patient.  
 Additionally, five of the 24 objectives related to Healthy People 2020 (HP 2020) relate to 
cardiovascular health and reduction of risk factors – including improvement of quality of life 
(Institute of Medicine, 2011). Quality of life is often affected by angina (Akyildiz & Ergene, 
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2014; Beltrame et al., 2009). One mechanism to equip patients to self-manage their angina is 
through increasing their knowledge and access to SLNTG.  
Project Design  
 The design for this DNP project was a non-experimental, cross-sectional, quantitative 
project using a descriptive survey. The survey was intended to assess knowledge, barriers, and 
current practice of NPs in the use of SLNTG in the SIHD patient.  Eysenbach (2004) suggests 
survey response rates less than 70% are often viewed with skepticism – but admits, the 70% or 
so is an arbitrary cut-off point.  
Sample.  This project included a convenient, nonprobability sample of NPs in NC 
registered with the NC Board of Nursing (BON). Power analysis was not done, as this was a 
convenience sample.  The electronic mail (e-mail) listserv was purchased from the NC BON. 
This sample included 5405 e-mail addresses of which 3156 were deleted, as these did not meet 
inclusion criteria; an additional 13 were removed because they did not have an e-mail address 
resulting in a total of 2236 participants who were sent an e-mail survey invitation to take the 
survey.  
Initially working with the Excel listserv, the following fields were deleted: full name, 
address, approval number, initial approval date, expiration date, compact state, and registered 
nurse (RN) certification number. In preparation for exporting the data file to Qualtrics® 
(Qualtrics ®,  Provo, UT, 2015), the web-based research survey software program that was used 
to design and administer the survey as well as download the survey data, the “name” column was 
replaced with a column labeled “firstname” and a second column labeled “lastname” and then 
each participant was renamed (literally) “firstname/lastname” in each cell to de-identify the data.  
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The participants were then further selected based on “practice type” and “primary and 
secondary specialty”.  Practice type/specialties included were primary care/internal 
medicine/family practice, nursing home/long-term care facility/assisted living facility/short-term 
rehabilitation facility, retail clinics, urgent/intermediate care facility as well as cardiology, 
nephrology and hospital (outpatient settings). The Excel file was then converted to a .csv 
(comma-separated values) file and imported to Qualtrics® to create e-mail panel for distribution 
of survey.     
Methods/instrument.  Based on the review of the literature, there were several areas of 
knowledge deficits identified in patients around the use of sublingual nitroglycerin. Those 
knowledge deficits included patients not being aware that they could take a SLNTG before an 
activity that induced angina (Fan et al., 2009; Gallagher, 2010); safety issues associated with the 
use of SLNTG and phosphodiesterase inhibitors (such as Viagra; Gallagher, et al., 2010); dosing 
intervals for the use of SLNTG (Fan et al., 2009, Gallagher et al., 2010, 2013); and when to 
replace their bottle of SLNTG (Gallagher et al, 2010; Zimmerman et al., 2000). The primary 
purposes of this DNP project and survey was to ascertain if NPs were knowledgeable in these 
areas, which are all reflected specifically in the 2012 SIHD Guideline (Fihn et al., 2012). The 
survey also looked at barriers to using SLNTG and current practice in the NP respondents. 
Therefore, based on these identified knowledge deficits in patients, the survey was designed to 
assess NPs’ self-reported knowledge. Additional safety issues covered in the 2012 SIHD 
Guideline was the limited or rare use of SLNTG in patients with hypertrophic obstructive 
cardiomyopathy (HOCM) and/or severe aortic stenosis (AS). This was addressed in the survey as 
well.  
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 No existing tool was found in the literature to assess these areas of knowledge in NP 
providers. Therefore, the author, over the course of one semester, developed a survey tool used 
in this project. The survey consisted of 21 questions and was expected to take 10-12 minutes to 
complete. The survey had a readability factor of 15.7 to 20.49, depending on which online word 
calculator used, which was consistent with college to graduate level readability per SMOG 
(Simple Measure of Gobbledygook; McLaughlin, n.d.; ReadabilityFormulas.com, n.d.; Trottier, 
2009). Most questions were “force-response”, with the exception of race, gender, and age.  
Eleven of the questions were demographic type questions to determine the respondents’ highest 
education in nursing, highest education as NP, NP title (certification), practice location by 
region, NP practice type, years of clinical practice in current role, prescribing privileges, 
awareness of SIHD guideline, gender, race/ethnicity and age. Additional questions sought to 
ascertain the frequency, respondents saw the following conditions that either are or can cause 
angina (or chest pain) and how likely they were to provide an initial prescription for SLNTG – 
chest pain/angina, coronary artery disease (CAD), status post (s/p) myocardial infarction (MI), 
s/p percutaneous coronary intervention (PCI), s/p coronary artery bypass grafting (CABG), 
hypertrophic obstructive cardiomyopathy (HOCM), and severe aortic stenosis (AS). Four 
scenario-type questions were used to further evaluate NP knowledge around the use of SLNTG 
as pre-medication for effort-induced angina, use with phosphodiesterase inhibitors, dosing 
sequence (as reported in the 2012 SIHD Guideline) and when patients are to replace their bottle 
of SLNTG. The remaining four questions related to factors that prevented the NP from 
prescribing SLNTG when clinically appropriate, frequency of assessing clinical guidelines 
(CGs), resources used and/or have access to look up CGs and/or medications, and lastly, barriers 
to use of evidence based healthcare.  Appendix D includes the Word version of the survey (as 
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downloaded from Qualtrics®) and The Nitroglycerin Handout developed as a downloadable 
attachment for the survey respondents on the use of SLNTG.  
 After multiple revisions of the survey with feedback from DNP faculty chair and 
committee member, face validity and content validity were obtained. Review of the survey by 
approximately eight DNP student colleagues provided face validity. Six expert NPs, two from 
primary care, two from cardiology and two from nephrology, were asked to provide content 
validity. A content validity index (CVI) of .84 and 1.00 was obtained during its development and 
revision, respectively (Polit & Beck, 2012). A limitation of the survey tool was the lack of 
construct validity and reliability prior to use (Polit & Beck, 2012). Multiple previews and pilot 
testing of the survey was done prior to launching it to the planned participants. 
Protection of human subjects. Research involving human subjects must take into 
consideration adherence to ethical principles and safety of participants (Polit & Beck, 2012). 
Institutional review board (IRB) approval was received for this project. See Appendix E for IRB 
Letters of Approval.  An amendment was also submitted after initial approval as the survey was 
revised; approval was granted. The setting for this e-mail survey allowed participants to 
complete the survey at their convenience on a computer that provided them with privacy. No 
Internet Protocol (IP) addresses were maintained. Additionally, because the data were aggregated 
and reported as a whole and not individually, the risk of identifying participants based on race, 
age, or location of practice was small. Consent to participate was implied when participants 
started the survey. Qualtrics® was used to administer the survey (Qualtrics®, Provo, UT, 2015). 
Data collected during the survey process were stored on the Qualtrics’® password protected 
website and a password-protected computer with adequate firewalls. Data will be stored for three 
years after completion of this project in accordance with Institutional Review Board regulations.  
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The e-mail survey was voluntary and anonymous, open only to those who received the e-
mail invitation. A Qualtrics® feature prohibited respondents from submitting multiple responses 
or forwarding their personalized e-mail link to unintended participants. No incentives were 
offered to entice participation.  
Data collection. To determine the NPs’ knowledge of and contraindications of the use of 
SLNTG in patients with SIHD, 2236 NPs in NC were invited to participate in this project 
through completion of the e-mail survey. Once the survey was ready for distribution, it was 
activated in Qualtrics® and the e-mail survey function was used. The narrowed e-mail list was 
imported into Qualtrics®, an e-mail introduction was devised (and approved by the IRB) and the 
e-mail survey was first launched on Tuesday, February 17, 2015. Two additional reminder e-
mails were sent out one-week apart on February 24, 2015 and March 3, 2015. The survey was 
closed on 3/11/15. A total of 347 surveys were returned, 226 surveys were used for the 
evaluation of data. This represents a ten percent response rate for the completed surveys.  
Incomplete surveys (n = 81) and those that selected hospital as practice type were not used in 
final analysis (n = 16). Also, those that elected to self-filter themselves out (n = 24) were not 
included in the 226 surveys used for evaluation of the data.  
Data analysis. Once the survey was closed, data was downloaded from Qualtrics® into 
both Excel and Statistical Package for Social Sciences (SPSS) version 22.  A codebook of the 
variables had already been created.  Several of the items were recoded. Qualtrics® had assigned 
a “code” to the answers, such as 9=yes, 10=no, or 1=yes, 2=no, therefore, several of those codes 
were changed for consistency. One major challenge in data analysis for this survey was 
determining how to “score” the survey. Much discussion ensued regarding this and it was 
recognized that scoring could probably be done a number of different ways. However, based on 
NURSE PRACTITIONER USE OF SUBLINGUAL NITROGLYCERIN  35 
the author’s intended purpose of the survey – which was to see if NPs expressed understanding 
of the use of SLNTG in SIHD as based on the 2012 SIHD Guideline, a correct response was 
given for only those answers that came directly from the guideline. Survey questions 9, 11, 12, 
13 and 14 were used primarily to measure knowledge of use of SLNTG. (See Appendix D)  
Question nine was used to see how likely NPs were to provide an initial prescription for 
SLNTG when clinically appropriate for conditions related to angina such as actual chest 
pain/angina, CAD, s/p MI, PCI, CABG, HOCM, and severe AS. (See Appendix D).  Question 
nine had seven parts (9-1, 9-2, etc.). Answers 9-1 (CP/angina), 9-2 (CAD), 9-3 (s/p MI), 9-4 (s/p 
PCI) and 9-5 (s/p CABG) were recoded as one (1) to indicate a “correct” response if fields 
“always (1) or very likely (2)” were selected as it is appropriate to provide a prescription for 
SLNTG in these patient conditions. Additionally “very unlikely (3) or never (4)” were recoded 
as zero (0) indicating incorrect response. Conversely, answers 9-6 (s/p HOCM) and 9-7 (severe 
AS) were recoded with a one (1) as “correct” if respondents selected “very unlikely (3) or never 
(4)” to provide initial prescription in these patient types as the 2012 SIHD Guideline suggest use 
of SLNTG is a relative contraindication for the patient with HOCM and should be avoided in 
patients with severe AS (Fihn et al., 2012). Likewise, “always (1) or very likely (2)” was recoded 
as zero (0) if selected as this would not be a demonstration of knowledge of these relative 
contraindications for the use of SLNTG.    
 The scenario questions (survey questions 11, 12, 13, 14) were also recoded. (See 
Appendix D).  Each scenario question had several yes/no responses (as to would they make the 
following recommendations – yes/no). Here again, design of the question was such that much 
discussion ensued about how to “score” the answers; it was decided, based on the purpose of the 
survey to note as a correct response (or a one[1]) for only the guideline selected answer (or 
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pivotal response or for the purpose of this project the “correct” answer). Therefore, participants’ 
responses were recoded as one (1) if selected the pivotal response and zero (0) if they did not.  
For the analysis of difference or relationship/association among practice specialties and 
knowledge of use of SLNTG – the proportion of number of correct answers for the same 
questions (9, 11, 12, 13, and 14) were analyzed. (See Appendix D). Knowledge scores per 
practice type (question 5) and NP title (question 3) were evaluated using frequency (n) and 
percentage (%) correct. (See Appendix D). Then cardiology was compared to all other practice 
sites. Cardiology was recoded as a one (1) and all other practice types were recoded as zero (0). 
Chi-square for independence was used for analysis.  
Once questions had been recoded and data analyzed, the determination of normality of 
the data was done (Moran et al., 2014). The distribution of the data helped determine which 
statistical tests were appropriate to use. Basic descriptive analysis with measures of frequency/ 
percentages were used on many of the variables. Mean and standard deviation was used for age 
and years of experience.  Additional analysis examined if an association existed between the 
variables. Appendix F, Table F1 shows portions of the survey questions, the research question it 
answers, and the statistical tests used for analysis.  
Resources Used/Cost Analysis 
 The cost analysis section included financial analysis that determined the practicality and 
cost-effectiveness of the project (Moran et al., 2014).  The majority of costs associated with this 
project was the author’s time. This author’s salary times the number of hours required (minimal 
400 hours) for completion of the project (500 hours spent on project), which included 
approximately 60 vacation days taken away from work to complete the requirements of the 
program was $23,255.50. Actual monetary outlay for the project, not including tuition and 
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books, was $225 for the purchase of the NC Board of Nursing e-mail list serv and approximately 
$40 for gift cards given to those NPs who provided content validity to the survey process. 
Additional cost to this student was the use of a professional statistician (approximately $1500) 
and professional editor for final journal article (approximately $250). Additional personnel 
resources pertinent to the project and not calculated out  based on their time would be the time 
spent by my committee chair, Dr. Robin Webb-Corbett and committee members, Dr. Candace 
Harrington, and Dr. Peter Wagner in providing feedback and guidance during the project design, 
survey design, implementation, and analysis. Additional personnel resources was time spent with 
the health science librarian, Qualtrics ® consultant with the College of Nursing (CON), 
statistician with the CON and IRB representative. This author’s time with these individuals is 
included in the 500 project hours. The total estimated cost of this project was approximately 
$28,956.56.  
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Chapter IV: Results 
Overview 
 This DNP project investigated the current knowledge and practice of NPs’ use of SLNTG 
in the SIHD patient and identified barriers reported regarding the use of SLNTG based on the 
2012 SIHD Guideline.  The Checklist for Reporting Results of Internet E-Surveys (CHERRIES) 
tool was the mechanism used to report the project results – see Appendix G for the completed 
CHERRIES tool (Eysenbach, 2004).  
Sample Characteristics 
 The e-mail listserv of NPs in NC used for this project was purchased from the NC Board 
of Nursing. The participants were then selected based on reported practice type and primary and 
secondary specialty. Inclusion criteria for practice type included primary care/internal medicine/ 
family practice, nursing home/long-term care facility/assisted-living or short-term rehabilitation 
facilities, retain clinics, urgent/intermediate care facilities, cardiology, nephrology, hospital, and 
other (to include those that may see this patient type, but their practice setting was not listed). 
Ultimately, those participants that selected hospital as their primary practice setting were 
eliminated. Also, participants taking the survey were given the option to self-filter themselves 
out of the survey by selecting “I do not see patients with stable ischemic heart disease (or chest 
pain)”.  
 Originally, 2236 e-mails sent to NPs in NC, 27 of the original e-emails were not 
deliverable. This left 2209 surveys sent for possible use. Qualtrics ® reported that 269 NPs 
completed the survey (2209-269 = 1940). One-thousand eight hundred and twenty-two surveys 
(1822) sent, were presumably never opened (1940-1822=118).Of this 118 that were opened, but 
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never finished, 79 were “partially completed”; 29 “opted out”; and 10 of the surveys’ “session 
expired” (79-29-10=118).  
Three hundred forty seven surveys were downloaded from Qualtrics ® to Excel for further 
analysis. A total of 81 (in Excel) were identified as “unfinished” (this was the 79 from above 
plus 2 that seemed to have opted out after finishing the survey).  The 81 “unfinished” surveys 
were deleted. As part of the original survey design, question five regarding practice type, 
provided the option for subjects getting to this point but electing to self-filter out by selecting the 
“I do not see patients with SIHD (or CP)” to do so. This eliminated another 24 surveys. Due to 
incongruence with the author’s objectives, those subjects who selected hospital as their primary 
practice site were discarded, eliminating an additional 16 surveys. Two hundred and twenty-six 
(n=226) surveys were used for analysis. This resulted in a 10% response rate for the e-mail 
survey.   
Descriptive statistics.  Demographic data for the group can be found in Appendix H.   
The majority of the NPs were female (93%, n=211)), approximately 84% (n=190) were 
white/Caucasian with a mean age of 47 years (SD = 10). Most participants (87%, n=197) had 
their Masters in Nursing Science (MSN), with approximately 70% (n=158) practicing as a 
Family Nurse Practitioner (FNP). The majority of participants (52%, n=118) practice in primary 
care/internal medicine/family practice followed by 14% (n=32) who practice in cardiology. The 
mean years of experience was 9.65 years (SD=7.64). Nearly all (99.1%, n=225) of the 
respondents reported having prescribing privileges and approximately 61% (n=137) 
acknowledged awareness of guideline for SIHD. The majority, approximately 59% (n=133), of 
the respondents practice in the Piedmont region of NC.  
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Major findings. This section contains survey findings relating to the knowledge of the 
use and contraindications of SLNTG and barriers to use of SLNTG by NPs responding to this 
survey. Knowledge as previously defined for the purpose of this survey was selection of the 
response taken directly from the 2012 SIHD Guideline. Questions 9, 11, 12, 13 and 14 relate 
primarily to the first two clinical project questions of NP understanding in the use of SLNTG for 
the self-management of angina as well as understanding of the contraindications for the use of 
SLNTG.  
Initially, question eight (see Appendix D) was designed to establish that chest pain or 
angina and other conditions often associated with angina are regularly seen in many adult clinics. 
NPs were asked how often they saw patients with the following seven diagnoses: chest 
pain/angina, CAD, status post (s/p) MI, s/p PCI, s/p CABG, and hypertrophic obstructive 
cardiomyopathy (HOCM) and/or severe aortic stenosis (AS). The NP respondents selected the 
frequency of seeing these type patients in their clinic on a Likert-type scale of daily, weekly, 
monthly, hardly ever or never.  Patients with the diagnosis of CAD was the most reported patient 
type seen. Approximately 51% of the NPs (n=115) reported seeing these patient types in their 
clinic on a daily basis. Figure I1 displays the remaining diagnosis types and frequency seen.  
 Knowledge statistics.  Question nine (see Appendix D) evaluated how likely NPs seeing 
patients with chest pain/angina, CAD, s/p MI, s/p PCI, s/p CABG, and HOCM and/or severe AS 
in clinic provided an initial prescription for SLNTG when clinically appropriate. Question nine 
was designed to assess knowledge, use (current practice) as well as contraindications to use of 
SLNTG.  The responses were recoded to reflect “always/very likely” or “very unlikely/never”.             
             Major findings. Only 41% (n=93) of the NPs would provide the initial prescription of 
SLNTG to patients with CAD. Fifty-nine percent (n=133) of the NPs responding to this survey 
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would rightly provide a prescription of SLNTG to patients with chest pain/angina. Whereas, only 
39% (n=88) would provide SLNTG prescription for patients s/p MI; 32% (n=72) for patients s/p 
PCI, and 30% (n=68) for patient’s s/p CABG.  Even though less than 5% (n=11) of NP providers 
responding to this survey saw patients with HOCM or severe AS on a daily basis, 88% (n=198) 
of those responding to the survey knew to “hardly ever/never” give an initial prescription for 
SLNTG to these patients. Figure I2 displays these results.  
 Questions 11-12 (see Appendix D) scenario questions measured knowledge of the use 
and contraindications of the use of SLNTG as outlined in the 2012 SIHD Guideline.  These 
questions corresponded to areas in the literature of patient deficits. This author identified four 
themes relative to the patient deficits found in the literature. These deficits included the use of  
SLNTG as premedication for effort-induced angina (Fan et al., 2009; Gallagher, 2010); SLNTG 
and the use of phosphodiesterase inhibitors (Gallagher, et al., 2010); dosing intervals for the use 
of SLNTG (Fan et al., 2009, Gallagher et al., 2010, 2013); and replacement of SLNTG 
(Gallagher et al, 2010; Zimmerman et al., 2000).  Each of these topics are covered in the 2012 
SIHD Guideline. A scenario was developed regarding the themes, and participants were provided 
with three to five recommendations to which they were to agree (yes) or disagree (no).  Selection 
of the correct recommendation as taken directly from the 2012 SIHD Guideline indicated 
knowledge of the guideline.  
 Similar to the body of evidence, only 35% (n=79) of NPs reported an awareness of the 
appropriate instructions for patients to premedicate with the SLNTG before activities that can 
cause angina (such as gardening, sexual activity, etc.). Seventy-seven percent (n=169) of NPs did 
report knowledge of the use of SLNTG and phosphodiesterase inhibitors. Nearly all (97%, 
n=219) reported knowledge regarding dosing instructions for SLNTG and 83% (n=187) reported 
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knowing when to instruct patients to replace their bottle of SLNTG.  Displayed in Figure I3 in 
Appendix I are the correct knowledge scores for all NPs per questions 11-14.  
 To answer the last clinical project question regarding any differences or associations 
between knowledge and practice type, this author analyzed knowledge questions 11 through 14 
and NP role (such as acute care NP, adult NP, family NP, etc.) and knowledge questions 11 
through 14 and practice type. It was of interest to see if NPs in one practice type or NP role were 
more knowledgeable about the topics of interest than another. Table J1 displays the percent 
correct by NP title and practice type.  
 Since the data for these questions were categorical in nature (NP role and practice type), 
the Chi-square test was used. However, once the contingency tables were ran and reviewed, the 
“minimum expected cell frequency” (Pallant, 2014, p. 227) was violated as several cells had 
expected counts less than five. Therefore, those results were not reported.  
 Given the above violation of expected cell outcome with individual practice type, the 
author elected to recode data to look at cardiology versus all other practice types. The data was 
collapsed and recoded as cardiology (1) and all others (0). A Chi-square was done on the new 
collapsed practice type (cardiology vs. all others) for each of the scenario questions and the 
pivotal responses from each (i.e., 11-3, 12-3, 13-3, and 14-2).  Each of these pivotal responses 
represented knowledge in areas on premedicating with SLNTG before activities causing angina 
(11-3); use of SLNTG and phosphodiesterase inhibitors (12-3); dosing of SLNTG (13-3); and 
when to replace the bottle of SLNTG (14-2). Chi-square was done with each permutation. Table 
J2 displays the percent correct per scenario question with the p-value for each Chi-square 
analysis.  
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 The responses to question 11-3, premedicating with SLNTG for effort-induced angina 
and practice type (cardiology vs. all others).  A Chi-square for independence (with Yates 
Continuity Correction) indicated no significant association between practice type (cardiology vs. 
all others) and knowledge of the use of SLNTG as premedication for effort-induced angina, χ2 (1, 
n = 226) = .219, p = .64, phi = .04. Forty-seven percent (47%, n=15) of NPs in cardiology 
compared to 34% (n=66) of all other NPs knew to recommend to patients to premedicate with 
SLNTG for effort-induced angina. Statistically, NPs working in cardiology were no more 
knowledgeable than all other practices. Table J2 displays this information. 
The responses to question 12-3, use of SLNTG and phosphodiesterase inhibitors and 
practice type (cardiology vs. all others). A Chi-square for independence (with Yates Continuity 
Correction) indicated an association between practice type (cardiology vs. all others) and 
knowledge of the use of SLNTG and phosphodiesterase inhibitors (like Viagra). χ2 (1, n = 226) = 
4.64, p = .03, phi = .159. Approximately 94% (n=30) of cardiology NPs answered the question 
correctly; whereas, approximately 75% (n=145) of non-cardiology NPs answered correctly. 
Statistically, this suggests NPs in cardiology are more knowledgeable than other NPs in all other 
practice types in the knowledge of potential interaction between SLNTG and phosphodiesterase 
inhibitors. Table J2 displays this information. 
 The responses to question 13-3, dosing of SLNTG and practice type (cardiology vs. all 
others).  A Chi-square for independence (with Yates Continuity Correction) indicated no 
significant association between practice type (cardiology vs. all others) and knowledge of the 
dosing schedule for SLNTG.  χ2 (1, n = 226) = .31, p = .57, phi = -.074. This suggests that 94% 
(n=30) of NPs working in cardiology know the correct dosing of SLNTG (per the 2012 SIHD 
Guideline) whereas 97% (n=188) of non-cardiology specialty NPs report knowledge of dosing 
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sequence. There was no statistically significant difference between the two groups. Table J2 
displays this information. 
 The responses to question 14-2, when to replace SLNTG bottle and practice type 
(cardiology vs. all others). A Chi-square for independence (with Yates Continuity Correction) 
found no significant association between practice type (cardiology vs. all others) and knowledge 
of when to tell patients to replace their SLNTG bottle. χ2 (1, n = 226) = .000, p = .99, phi = .018.  
Lastly, 84% (n=27) of cardiac specialty NPs reported knowing when to have patients replace 
their SLNTG; and 82% (n=159) of non-cardiac specialty NPs knew this information. Here again, 
there was no statistical difference between knowledge of NPs working in cardiology and those in 
other practice types.  Table J2 displays this information.  
 Overall, the NPs that responded to this electronic survey were aware of correct dosing of 
SLNTG, use of SLNTG with phosphodiesterase inhibitors, and when to tell patients to replace 
their SLNTG.  However, NPs respondents were less knowledgeable about SLNTG as 
premedication for effort-induced angina.  The only statistically significant finding noted when 
comparing NPs working in cardiology to all other practice types, was their knowledge in the 
contraindication of the use of SLNTG and phosphodiesterase inhibitors; NPs in cardiology were 
more knowledgeable about this information. However, there was no statistically significance in 
knowledge of NPs working in cardiology compared with all other practice types around the use 
of SLNTG as premedication for effort-induced angina, dosing sequence of SLNTG and/or when 
to tell patients to replace their SLNTG.  
Barriers statistics. One other aspect of the survey (question 16) looked at NPs’ use of 
clinical practice guidelines (CPG) in general. (See Appendix D). Since this practitioner was 
evaluating the use of the 2012 SIHD Guideline, it was asked how often NPs look up CPGs. 
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Twenty five percent of the respondents reported looking up CPG two to three times per week, 
followed by 22% (n=50) who look up CPG daily.  
Major findings. Question 15 of the survey was to inquire as to what factors NPs reported 
as barriers to prescribing SLNTG when clinically appropriate (See Appendix D). Approximately 
62%  (n=142) of NPs identified they had no problems with writing an initial or refill prescription 
for SLNTG; while 57.5% (n=131) NPs had no problems writing refill for SLNTG once initial 
prescription provided by cardiology provider.  Other factors reported that prevent NPs from 
prescribing SLNTG included the belief that all patients with chest pain should go to the hospital 
(7.5%, n=17) or they report practicing with a supervising physician who believes patients with 
stents or CABG do not need a prescription for SLNTG (0.9%, n=2). See Appendix K for list of 
all responses to remaining survey questions (questions 15, 16, 17, and 18). 
Questions 17 assessed what resource(s) NPs had access to and/or used to look up CPGs 
or medication information (see Appendix D). Eighty-four percent (n=190) reported assess to 
asking their supervising physician; followed by 82.7% (n=187) had access to 
Google/Bing/Yahoo and 75% (n=169) had access to Up-To-Date. Sixty percent (n=137) reported 
having asked (or used) their supervising physician and 60% (n=137) used Up-To-Date. Fifty-
seven percent (n=128) of NPs had also used Google/Bing/Yahoo and/or Epocrates to look up 
CPG or medication information.  Further analysis revealed that most NPs respondents had up to 
five years of work experience (n=94, 42%). Of those 94 NPs, 60 (64%) had asked their 
supervising physician about CPGs and/or medication information.  See Appendix K, Figure K1 
for further details regarding years of work experience and NPs who asked their supervising 
physician.  
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Finally, barriers that prevent NPs from consistently practicing evidenced-based 
healthcare (EBHC), the majority (61%, n=127) reported no barriers to practicing EBHC; 
followed by “try to use guidelines, but patients are not compliant” (23%, n=53), whereas, 22% 
(n=50) selected “not enough time to stay informed.”   
Summary of Results 
 This survey assessed NPs and their knowledge and use of SLNTG according to the 2012 
SIHD Guideline. Contraindications in the use of SLNTG and barriers NPs self-reported to 
providing a prescription for SLNTG were also assessed.  Nearly 61% (n=137) of NPs report 
being aware of the guidelines for the diagnosis and management of patients with SIHD and 51% 
(n=115) of respondents see patients with CAD on a daily basis. Yet only 41% (n=93) of NPs 
would provide an initial prescription for patients being seen in their clinic. In addition, only 35% 
(n=79) of NP respondents seem aware of the appropriate recommendation to advise patients to 
use SLNTG as premedication for effort-induced angina. Similarly, only 24% (n=10) of patients 
knew to use SLNTG in this way (Fan et al., 2009). An interesting finding was that the majority 
of NP respondents (62%, n=142) reported no barriers to providing an initial or refill prescription 
for patients when clinically appropriate, followed by nearly 58% (n=131) having no problems 
providing a refill for SLNTG once initial prescription provided by cardiology provider.  
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CHAPTER V: Discussion 
 Survey projects are a way to obtain descriptive information using self-reported data 
(Melnyk & Fineout-Overholt, 2015). This DNP project assessed knowledge, barriers, and current 
practice as reported by NPs in adult care clinical settings in their use of SLNTG based on the 
2012 SIHD Guideline. One outcome of such evaluation was the dissemination of findings in 
such a way to inform and educate clinicians in the reported findings and areas of improvement. 
The overall encompassing goals of information from this project are concurrent quest of better 
care for individuals, better health for populations, and lower per capita costs of health care 
(Berwick, Feeley, & Loehrer, 2015) as implied by the Institute of Health’s Triple Aim (IHI-
Institute of Health, 2014).   
 When asked how often NPs saw patients in their clinics with clinical diagnoses 
associated with the symptoms of CP/angina or with conditions that can present with angina, the 
majority of NPs reported seeing patients with CAD on daily basis, followed by CP and s/p MI 
weekly. NPs reported that monthly it was common to see patients who were s/p PCI or CABG 
whereas; patients with HOCM and/or severe AS were hardly ever seen in their clinics.  
Only 59% (n=133) of the NPs report they would provide an initial prescription for 
SLNTG to the patients with CP/angina; whereas 41% (n=93) would not. Forty-one percent 
(n=93) or less of NPs would provide an initial prescription for SLNTG to patients with CAD, s/p 
MI, PCI and/or CABG.  As appropriate, the majority of NPs (88%, n=198) would be very 
unlikely or would never provide a prescription for SLNTG in the patients with HOCM and/or 
severe AS. This suggests that 12% (n=27) of NPs would provide a prescription for SLNTG to 
these patient with HOCM and/or severe AS, which according to the 2012 SIHD Guideline is 
contraindicated (Fihn et al., 2012).  
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When given a scenario type question and asked if they would (yes) or would not (no) 
make the following recommendations (see Appendix D), 65% (n=147) of NPs would not suggest 
the use of SLNTG as a pre-medication for effort-induced angina. Nearly all, 97% (n=219), report 
knowing the dosing sequence of SLNTG as per the 2012 SIHD Guideline. Seventy-seven percent 
(n=174) of NPs are aware of recommendations around the use of SLNTG and phosphodiesterase 
inhibitors. Eighty-three percent of NPs report knowing when to have patients replace their bottle 
of SLNTG.  
Implications of Findings  
Walton-Shirley’s (2014) commentary on the lack of availability of SLNTG in patients 
clinically appropriate to have a prescription initiated this author’s investigation. Further 
examination of the literature found no information on NP or physician provider knowledge of the 
use of SLNTG. The few studies that looked at knowledge and use of SLNTG were from the 
patients’ perspective. These studies suggested that many patients, if they had a prescription for 
SLNTG, did not always report an understanding of how or when to correctly use the medication. 
Chronic stable angina (CSA) in SIHD is common and often seen in most adult care offices (Go 
et al., 2014).   
For practice.  In the 2012 SIHD Guideline, Fihn and colleagues outlined the goals for 
treating patients with SIHD as twofold: to decrease the possibility of death while maintaining 
health and function. Two objectives cited to achieve these goals were preserved or improved 
functional capacity and quality of life while eliminating ischemic symptoms (Fihn et al., 2012).   
One strategy used to achieve improved functional capacity, quality of life and elimination of 
ischemic symptoms is with GDMT, such as the use of SLNTG, while avoiding drug interactions 
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and unwarranted side effects (Fihn et al, 2012). These project findings have implications for 
NPs’ clinical practice and the use of SLNTG related to achievement of the above objectives.   
Evidence-based practice (EBP) is the use of best available evidence, combined with 
nursing expertise while maintaining the values and preferences of individuals, families and 
communities (Sigma Theta Tau, 2004). Clinical practice guidelines are one resource for 
providing evidence-based healthcare.  The majority (24.8%, n=56) of NPs surveyed for this 
project reported looking up CPGs two to three times a week. Most, nearly 61% (n=127), reported 
no barriers to practicing EBP (or evidence-based healthcare); yet evidence from the responses 
suggest a discordance between their perception of using EBP and their knowledge of the 
concepts evaluated in this survey. 
      Survey findings suggest opportunities for improvement in the care for the SIHD patient 
population.  Congruent with the literature (Walton-Shirley, 2014; Gallagher et al., 2010), patients 
often do not have a prescription for SLNTG when clinically appropriate (i.e., diagnosis of CAD). 
In this survey, only 41% (n=93) of NPs reported, they were to likely provide an initial 
prescription for SLNTG in the CAD patient. Yet, when asked what factors prevent the NP from 
providing a prescription for SLNTG when appropriate, nearly 62% (n=140) reported no 
problems with providing an initial (or refill) prescription for SLNTG. Respondents to the survey 
may have provided socially desirable responses to the question regarding factors preventing them 
from prescribing SLNTG when clinically appropriate (Dillman, Smith, & Christian, 2014).   
Likewise, the literature on patient knowledge suggested that only 24% (n=10) of patients 
knew they could use SLNTG as a pre-medication for effort-induced angina (Fan et al., 2009; 
Gallagher, 2010). This was very similar to the survey’s finding that only 35% (n=79) of NPs 
who would make this recommendation as evaluated in scenario question 11. (See Appendix D).  
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Though 77% (n=174) of NPs who were aware of the contraindications between the use of 
SLNTG and phosphodiesterase inhibitors, still 23% (n=52) of NPs appear unaware of this 
danger. This finding was in contrast with Fihn et al.’s (2012) recommendation that attention be 
given to avoid drug interactions for successful management of angina.  
The majority of NPs, 97% (n=219), reported understanding dosing instruction for 
SLNTG as based on the 2012 SIHD Guideline. Lastly, 83% (n=187) of NPs are aware of when 
to tell patients they should replace their bottle of SLNTG. Keeping a current bottle of SLNTG 
available for use when needed for self-management of angina was imperative for quality of life, 
as well as improved functional capacity.  
 For education. Past research suggested knowledge deficits in patients in the correct use 
and understanding of SLNTG (Fan et al., 2009; Gallagher, et al., 2010, 2013; Zimmerman et al., 
2009). The findings of this NP survey identified NP knowledge deficits as well. Knowledge 
deficits identified in the NP survey included the use of SLNTG as a premedication for exercise 
induced angina and potential interactions between SLNTG and phosphodiesterase inhibitor use. 
Therefore, there are opportunities for ongoing clinical education for patients and NP providers. 
The development of a chest pain action plan would provide evidence-based clinical care for 
patients with SIHD. Therefore, post-doctoral efforts by this author will include the development 
of a chest pain action plan for dissemination.  
The author, as a DNP prepared graduate, is well positioned to disseminate the survey 
findings. As part of this DNP project a handout for providers which bulleted many aspects of the 
use of SLNTG was developed. After completing the survey, the handout was available for 
download. In addition, a manuscript for a clinical professional journal will be prepared to 
increase dissemination of the educational awareness information to NP colleagues. Lastly, 
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survey findings can be diffused further through professional presentations and one-on-one with 
colleagues and while precepting NP students.    
For scholarship. Boyer’s (1990) definition of scholarship in nursing (as cited by the 
American Association of Colleges of Nursing [AACN], 1999) is defined as  
… those activities that systematically advance the teaching, research, and practice of 
nursing through rigorous inquiry that 1) is significant to the profession, 2) is creative, 3) 
can be documented, 4) can be replicated or elaborated, and 5) can be peer-reviewed 
through various methods (p. 2).  
Clinical scholarship as related to this DNP scholarly project was an opportunity to close the gap 
between research and practice (Moran et al., 2014).  
The literature suggested there is a discordance that exists between guideline 
recommendations and actual SLNTG prescribing practices. Previous research regarding the use 
and knowledge of SLNTG in the SIHD patient has been from the patients’ perspective. This 
project was an original attempt at evaluating NP providers’ knowledge of the knowledge, 
barriers, and current practice of the use of SLNTG in the SIHD patient. The findings from this 
DNP project can be translated into clinical practice to improve the knowledge base of and 
subsequently improve the quality of life for individuals with SIHD. (Sigma Theta Tau Clinical 
Scholarship Task Force, 1999). Opportunities exist for ongoing work in this clinical area. As 
previously discussed, the tool, developed specifically for this project needs further work for 
reliability and construct validity. Lastly, a poster or podium presentation of the project findings 
at a state or national NP conference is planned.  
Limitations 
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The greatest limitation in this project design was the development and design of the 
actual survey. The author found no pre-existing instrument to measure NP knowledge in this area 
of clinical interest and the development of the survey was pivotal to the success of the 
information gathered. Although this survey was revised multiple times during its development, 
there are still areas for ongoing improvement.   Most notable to any future endeavor, it is critical 
to clearly identify the concept to measure to facilitate the identification of the appropriate tool 
and statistical analysis (Pallant, 2013).  Future efforts in survey projects by this author would 
include self-directed continuing education course work on survey design and/or seeking out a 
national expert on survey design who could provide feedback to improve content and face 
validity. One could also change the methodology of the project to include a focus group to assess 
knowledge.  
In hindsight, involvement of a statistician during survey design would have allowed for 
more stringent data analysis techniques. This student felt that factor analysis and reliability of the 
survey were beyond the expectations of the program and the lack of reliability and factor 
analysis of the survey items is a limitation.  
 A specific revision to the Nitroglycerin Handout embedded as a link at the end of the 
survey for participants would the inclusion of the use of SLNTG as a pre-medication for effort-
induced angina.  
Generalizability.  Factors affecting the generalizability of these DNP project findings are 
the use of a convenience sample, use of self-reported data, and the low survey response rate. 
Power analysis was not done since a convenience sample was used. Adams, Soumerai, Lomas 
and Ross-Degnan (1999) concluded there was often an over-estimation of adherence to practice 
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guidelines when using self-reported means, such as a survey. The response rate of only 10% was 
a limitation that would affect generalizability.  
The results of the project are generalizable only to the sample surveyed, but the findings 
reveal opportunities for further education of NP providers who in turn would be equipped to 
facilitate patient education.  To enhance the generalizability of these findings, further 
development of the tool is needed in the areas of reliability/construct validity and factor analysis. 
Increasing the sample size to a regional or national NP database would contribute to 
generalizability. The project findings serve to inform NP practice in NC and provide a 
foundation to fill a noted gap in the nursing knowledge for the provision of high quality 
evidence-based practice in the SIHD patient populations.   
Delimitations 
 Delimitations are decisions made by the author from the beginning. One delimitation for 
this project was in sample selection. This DNP student elected to begin evaluation of knowledge 
with fellow NPs in NC.  Physicians and physician assistants were not included in this survey. 
Additionally, it was decided to limit respondents to adult care settings and cardiac medicine, and 
did not include those from cardiac surgery because providers in cardiac surgery often follow this 
patient population short-term and in the initial post-operative phase after CABG. Therefore, 
cardiac surgery providers would generally expect patients who experience chest pain to report to 
emergency room for further evaluation instead of self-managing their symptoms. In addition, the 
author, elected not to use responses from participants who reported the hospital as their primary 
setting, as they do not generally follow patients on a long-term basis in the clinic setting.   
 The process for assigning (or scoring) knowledge was identified as a potential issued 
during survey design. Different scoring methods could have been used.  
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 One additional delimitation was the strict use of the 2012 SIHD Guideline (Fihn et al., 
2012). As previously discussed, the ACCF/AHA published the 2014 Focus Update to the 2012 
SIHD Guideline; however, the newer guideline discussed primarily diagnostic testing and added 
nothing to the GDMT section as addressed in the 2012 SIHD Guideline related to SLNTG. Fihn 
and colleagues (2014) under the GDMT section only elaborated on the use of Chelation Therapy 
and EECP both for the treatment of angina. In addition, at least two survey respondents 
mentioned that the dosing of SLNTG had changed from instructing patients to call 911 after 
taking their third SLNTG five minutes apart to calling after the first SLNTG. The dosing 
schedule used in this project was taken from the 2012 SIHD Guideline, which instructed 
providers to have patients call 911 after the third SLNTG if relief does not occur. The 2013 
ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction (STEMI; 
O’Gara et al., 2013; Rosenberg, 2005) reflects an updated recommendation to have patients call 
911 after taking only one SLNTG. The intent behind this new recommendation was to avoid 
delay in arrival of EMS services. However, for the purpose of this DNP project, the SIHD patient 
is the focus, not the patient with a STEMI.  
Recommendations 
 Few NPs responding to this DNP survey were aware of the use of SLNTG as pre-
medication for effort-induced angina. Therefore, one lesson learned from this evaluation of NP 
knowledge is the opportunity to equip providers and patients with an option to improve 
functional capacity by instructing them to use SLNTG as a pre-medication for effort-induced 
angina.  
 Findings indicated opportunities for improvement in the use of SLNTG from the NPs’ 
perspective. As practitioners, NPs need to recall the basics in the use of SLNTG. Angina affects 
NURSE PRACTITIONER USE OF SUBLINGUAL NITROGLYCERIN  55 
quality of life (Akyildiz & Ergene, 2014; Beltrame et al., 2009) and is associated with long-term 
anxiety, depression and impaired physical functioning (Beatty et al., 2014; Jespersen et al., 
2013). The literature suggests there is a discordance between patients needing a prescription for 
SLNTG and those patients who have a prescription as well as not understanding the use and/or 
purpose of SLNTG. The findings of this DNP project support similar findings of NP providers 
completing this survey. Therefore, additional education of providers or even increased awareness 
in these basic knowledge items in the use of SLNTG may improve the quality of care in the 
SIHD patient population. 
Overall Conclusion 
The American Association of College of Nursing’s (AACN) Essentials of Doctoral 
Education for Advance Practice Nursing (AACN, 2006) served as a roadmap of required 
elements for completion of this DNP program.  From the selection and exploration of a clinical 
issue to the completion of the project to this point, this author believes they have met those 
requirements. Appendix K reviews aspects of the project as they relate to the eight essentials.   
As a NP working in an adult cardiology practice in eastern NC, this student appreciated 
the clinical scholarship of delving more deeply into the management of patients with SIHD 
(AACN Essential II). The initial commentary from Walton-Shirley (2014) suggested the need for 
a “global practice-improvement initiative” (para. 1) exploring nitroglycerin prescribing provided 
the first-step for which this DNP scholarly project was begun. Review of the literature found 
little on this topic and what literature was discovered was from the patients’ perspective (AACN 
Essentials II, III).  
Based on the research findings that patients often do not possess either an actual 
prescription for SLNTG nor the knowledge to appropriately use SLNTG, this author proceeded 
NURSE PRACTITIONER USE OF SUBLINGUAL NITROGLYCERIN  56 
to explore NPs’ knowledge and use of SLNTG in the SIHD patient population.  Aspects of 
cardiovascular care are included in five of the 24 objectives for HP 2020 including improvement 
of quality of life (AACN Essential III).  Helping patents better self-manage their angina with 
SLNTG has the potential to improve their quality of life, decrease the misuse or overuse of 
healthcare resources, and improve overall care for this patient population (AACN Essential V).    
A major portion of this DNP project was the development of an original tool used to 
assess NP knowledge around the use of SLNTG. The basis for survey research was reviewed and 
the tool was developed (AACN Essential III). Collaboration with the DNP Project Committee 
Chair and Members, statistician, NP colleagues and one of the authors whose work was 
referenced for this project was required in the development of the tool (AACN Essential VI). 
Noting the limitation of a tool lacking statistical reliability and validity, the results proved 
interesting and paralleled some of the knowledge deficits of cardiology patients. As discussed, 
though the tool had some weakness or limitations for use, the information obtain was informative 
and often paralleled the findings of patients as mentioned in the literature. Technology was used 
in the DNP project through use of Qualtrics ®, Excel, SPSS and many other aspects of computer 
technology (AACN Essential IV). 
Findings from this DNP Project provided an opportunity to remind practitioners in many 
health care settings about the use of SLNTG (AACN Essential VIII).  Educating NPs on the use 
of SLNTG as a premedication for effort-induced angina and reminding them of the potential 
interaction between phosphodiesterase inhibitors are two knowledge deficits identified in survey 
respondents. Ongoing efforts to educate both providers and patients will enhance the care 
provided to the SIHD patient population and add to the knowledge and scientific underpinnings 
of nursing practice (AACN Essentials I, VII).  
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In closing, patients with SIHD are seen in many healthcare settings. Angina is one 
manifestation of SIHD. Guideline-directed medical therapy is an important aspect of the care for 
these patients. Sublingual nitroglycerin is a mainstay of GDMT for these patients with SIHD 
with anginal symptoms. This DNP project demonstrated opportunities for NPs to get back to the 
basics in caring for these patients with SIHD by re-educating themselves and their patients in the 
use and contraindications for SLNTG. Equipping patients with tools to self-manage their 
symptoms can help improve quality of life, increase physical functioning and decrease overall 
healthcare costs.  
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Figure B: Diffusion of Innovation Theory-Theoretical Model 
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Figure C: Timeline for DNP Project/Course Work  
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Appendix D 
 
D1: Word version (as downloaded from Qualtrics) of DNP project Survey 
 
The Use of Sublingual Nitroglycerin 
 
SURVEY OF NURSE PRACTITIONERS' KNOWLEDGE, BARRIERS, AND CURRENT 
PRACTICE IN USE OF SUBLINGUAL NITROGLYCERIN IN THE STABLE 
ISCHEMIC HEART DISEASE PATIENT 
       
You are being invited to participate in an investigative survey, titled “Nurse Practitioners’ 
Knowledge, Barriers, and Current Practice in the Use of Sublingual Nitroglycerin in the Stable 
Ischemic Heart Disease (SIHD) Patient” being conducted by Melinda Matthews, ANP- BC a 
DNP Student at East Carolina University, College of Nursing.      
 
The goal is to identify knowledge, barriers, and current practice as reported by nurse 
practitioners (NPs) practicing in North Carolina in primary care and specialty clinics in the use 
of sublingual nitroglycerin in the SIHD patient.     
    
The survey will take approximately 10-12 minutes to complete. Participation in this anonymous, 
voluntary survey implies consent.  There is no penalty for not taking part in this investigative 
survey. Please try and complete the survey in one sitting or if need to stop and return, please 
return to the same computer to complete.       
 
Please call Melinda Matthews, ANP at 252-316-2067 for any research related questions or the 
Office of Research Integrity & Compliance (ORIC) at 252-744-2914 for questions about your 
rights as a research participant. 
 
Q1 What is your highest level of education in nursing? 
 Diploma RN (1) 
 ADN (2) 
 BSN (4) 
 BS (5) 
 MSN (6) 
 DNP (7) 
 PhD (8) 
 Other (9) 
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Q2 What is your highest level of education as Nurse Practitioner 
 Certificate (1) 
 Graduate (2) 
 
Q3 Please indicate the title that best describes your current Nurse Practitioner role: 
 Acute Care Nurse Practitioner (ACNP) (1) 
 Adult Nurse Practitioner (ANP) (2) 
 Family Nurse Practitioner (FNP) (3) 
 Gerontology Nurse Practitioner (GNP) (4) 
 Adult/Gerontology Primary Care Nurse Practitioner (AGPCNP) (5) 
 Other (7) 
 
Q4 Please indicate which region in North Carolina (NC) your primary Nurse Practitioner 
practice is located: 
 Coastal Plains (Beaufort, Bertie, Bladen, Brunswick, Camden, Carteret, Chowan, 
Columbus, Craven, Cumberland, Currituck, Dare, Duplin, Edgecombe, Gates, Greene, 
Halifax, Harnett, Hertford, Hoke, Hyde, Johnston, Jones, Lenoir, Martin, Nash, New 
Hanover, Northampton, Onslow, Pamlico, Pasquotank, Pender, Perquimans, Pitt, Roberson, 
Sampson, Scotland, Tyrell, Washington, Wayne, Wilson) (1) 
 Piedmont (Alamance, Alexander, Anson, Cabarrus, Caswell, Catawba, Chatham, Cleveland, 
Davidson, Davie, Durham, Forsyth, Franklin, Gaston, Granville, Guilford, Iredell, Lee, 
Lincoln, Mecklenburg, Montgomery, Moore, Orange, Person, Randolph, Richmond, 
Rockingham, Rowan, Stanley, Surry, Union, Vance, Wake, Warren, Yadkin) (2) 
 Mountains (Alleghany, Ashe, Avery, Buncombe, Burke, Caldwell, Cherokee, Clay, Graham, 
Haywood, Henderson, Jackson, Macon, Madison, McDowell, Mitchell, Polk, Rutherford, 
Swain, Transylvania, Watauga, Wilkes, Yancey) (3) 
 
Q5 Please indicate the practice type where you spend the majority of your time as a Nurse 
Practitioner: 
 Primary Care Setting/Internal Medicine/Family Practice (1) 
 Nursing Home/Long-term Care Facility/assisted Living or Short-term Rehabilitation (2) 
 Retail Clinic (3) 
 Urgent or Intermediate Care (4) 
 Specialty Clinic: Cardiology (5) 
 Specialty Clinic: Nephrology (6) 
 Hospital (7) 
 Other (10) 
 I do not see patients with stable ischemic heart disease (or chest pain) (11) 
If I do not see patients with ... Is Selected, Then Skip To This concludes the survey. Thank 
you ... 
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Q6 How many years have you been in clinical practice in your current Nurse Practitioner 
role? ___ (will be free text answer) 
 
Q7 Do you have prescribing privileges? 
 Yes (9) 
 No (10) 
 
Q8 In your day-to-day practice, how often do you see a patient with the diagnosis of: 
 Daily (1) Weekly (2) Monthly (3) 
Hardly ever 
(4) 
Never (5) 
Angina or chest 
pain (CP) (1) 
          
Coronary artery 
disease (CAD) 
(2) 
          
Status post 
myocardial 
infarction (S/p 
MI) (3) 
          
Status post 
percutaneous  
coronary 
intervention 
(s/p PCI) (4) 
          
Status post 
coronary artery 
bypass grafting 
(s/p CABG) (5) 
          
Hypertrophic 
obstructive 
cardiomyopathy 
(HOCM) (6) 
          
Severe aortic 
stenosis (AS) 
(7) 
          
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Q9 As a general rule, how likely are you to provide an initial prescription (RX) for 
sublingual nitroglycerin in the following conditions? 
 Always (1) Very Likely (2) 
Very Unlikely 
(3) 
Never (4) 
Angina or chest 
pain (CP) (1) 
        
Coronary artery 
disease (CAD) 
(2) 
        
Status post 
myocardial 
infarction (S/p 
MI) (3) 
        
Status post 
percutaneous 
coronary 
intervention (s/p 
PCI) (4) 
        
Status post 
coronary artery 
bypass grafting 
(s/p CABG) (5) 
        
Hypertrophic 
obstructive 
cardiomyopathy 
(HOCM) (6) 
        
Severe aortic 
stenosis (AS) (7) 
        
 
 
Q10 Are you aware of the guidelines for diagnosis and management of patients with stable 
ischemic heart disease? 
 Yes (1) 
 No (2) 
 
In the following scenarios, please provide your response(s) 
 
Q11 Ms. Jones, a 56 year old white female, enjoys working in her garden. She finds after 
about 15 minutes of working at moderate pace, she develops chest pain (her typical 
symptoms of left chest pain that radiates to her jaw). She usually stops working in the 
garden and goes in the house, rests and after about 5 minutes, the pain resolves on its own. 
She is on metoprolol (a beta-blocker), Imdur (long-acting nitrate), Lisinopril (ACE-
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inhibitor) and Ranolazine (Ranexa) and has a prescription for sublingual nitroglycerin. 
She also has hypertension. Your recommendations include: (Select yes or no for each 
statement)   
 Yes (18) No (19) 
You inform her she is doing 
the right thing by going in the 
house and resting, as one has 
to be careful and not over do 
it with heart disease. (1) 
    
You consider increasing her 
Imdur and/or Ranexa (2) 
    
You advise her to take a 
sublingual nitroglycerin 5-10 
minutes before the planned 
activity (gardening) and see if 
that will allow her to work 
longer in her garden before 
developing chest pain, 
possibly up to 30-40 minutes 
before development of 
symptoms. (3) 
    
You advise her to 
immediately call 911 with 
any chest pain. (4) 
    
 
 
Q12 Mr. Thompson is a 70 yo male with coronary artery disease, Erectile Dysfunction, and 
hypertension. He and his wife report being sexually intimate. His current medications 
include beta-blocker, ACE-inhibitor, Aspirin, statin and Ranolazine (Ranexa). He requests 
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a prescription (RX) for both Viagra and Sublingual Nitroglycerin. What instructions 
MUST you provide?  (Select yes or no for each statement) 
 Yes (9) No (10) 
None, as he is not on a long-
acting nitrate, so use of 
phosphodiesterase inhibitors, 
such as Viagra is okay. (1) 
    
Advise him it is okay to have 
a prescription for Viagra, as 
he is not on a long-acting 
nitrate. But withhold the 
prescription for sublingual 
nitroglycerin. (2) 
    
Advise him it is okay to have 
prescription for both Viagra 
and sublingual nitroglycerin 
but caution him that he should 
not use the sublingual 
nitroglycerin within 24 hours 
of using the Viagra. (3) 
    
Suggest he should avoid 
having sex with his wife with 
his heart disease. (4) 
    
 
 
Q13 Ms. Smith, a 68 year old white female with hypertension, diabetes, hyperlipidemia, 
stage 3 chronic kidney disease as well as coronary heart disease with previous history of 
myocardial infarction 2 years ago, and now status post myocardial infarction 3 days 
ago.  She did not get a stent at that time, but is being treated medically. She is on the usual 
medications, including aspirin, statin, Beta-Blocker, ACE-inhibitor and Ranexa. She is 
NURSE PRACTITIONER USE OF SUBLINGUAL NITROGLYCERIN  72 
given a RX for sublingual nitroglycerin as well as Instructions for use, which should 
include:  (select yes or no for each statement) 
 Yes (10) No (11) 
Once she obtains the RX for 
sublingual nitroglycerin, be 
sure and transfer them 
directly to her pillbox that she 
keeps in her purse. (1) 
    
Remind her that the pills 
should be used daily whether 
she is having CP or not. (2) 
    
Instruct her to place a pill 
under her tongue if develops 
chest pain (CP) that does not 
resolve w/ rest after a few 
minutes. Instruct her to take 1 
tablet every 5 minutes (up to 
3 tabs) and if still having CP 
with the 3rd one, she should 
call 911. (3) 
    
Advise her to remain standing 
while taking the sublingual 
nitroglycerin as it works 
better that way. (4) 
    
Stop the medication 
immediately if she 
experiences a headache or 
blurred vision, as this 
suggests an uncommon 
reaction to the medication. (5) 
    
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Q14 A patient should be instructed to replace their bottle of sublingual 
nitroglycerin: (select yes or no for each statement)    
 Yes (9) No (10) 
According to the expiration 
date on the side of the bottle 
(as long as the bottle has not 
been opened) (1) 
    
6-12 months after they have 
opened the bottle (2) 
    
Only after they have used all 
their pills, no matter how 
long they have had them. (3) 
    
 
 
Q15 What factors prevent you from prescribing sublingual nitroglycerin when clinically 
indicated? (select all that apply) 
 I am uncomfortable writing for this medication – afraid it will harm my patient. (1) 
 I have never written a prescription for sublingual nitroglycerin and do not plan to write one. 
(2) 
 My supervising physician does not believe patients who have had stents or coronary bypass 
surgery (CABG) need a prescription for sublingual nitroglycerin. (3) 
 I have no problems writing an initial or refill prescription for sublingual nitroglycerin. (4) 
 I have no problems refilling sublingual nitroglycerin once the initial prescription provided by 
a cardiology provider (5) 
 I do not provide prescription for sublingual nitroglycerin because if patient having chest pain, 
they should go to the emergency room for further evaluation. (6) 
 I do not write prescriptions in the practice where I work. (7) 
 
Q16 How often do you look up clinical guidelines for a specific problem/disease/ disorder? 
 Never (11) 
 Less than Once a Month (12) 
 Once a Month (13) 
 2-3 Times a Month (14) 
 Once a Week (15) 
 2-3 Times a Week (16) 
 Daily (17) 
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Q17 Please indicate if you have access and if you use the following resources for reviewing 
clinical guidelines or medication information  (select all that apply): 
 I have access (1) I have used (2) 
Google/Yahoo/Bing (1)     
Google Scholar (2)     
UpToDate (3)     
National Guideline 
Clearinghouse (4) 
    
American Heart Association 
(5) 
    
Medscape (6)     
Lexicomp (7)     
Micromedex (8)     
Epocrates (9)     
I have access to a health 
science library at/through my 
practice - several resources 
available. (10) 
    
I usually also confer with my 
NP colleagues (11) 
    
I ask my supervising 
physician (12) 
    
 
 
Q18 The following are reasons (barriers) to why I may not consistently practice evidence-
based healthcare (select all that apply): 
 Lack of familiarity or awareness of available clinical guidelines. (1) 
 Not enough time to stay informed. (2) 
 Lack of access to guidelines. (3) 
 I do not typically agree with guidelines. (4) 
 Guidelines are too "cookbook". (5) 
 I find that the guidelines usually do not provide the expected outcomes. (6) 
 I try to use guidelines, but my patients are not compliant. (7) 
 I do not have time to review the information in guidelines with my patients. (8) 
 The practice with which I work does not endorse the use of clinical guidelines. (9) 
 I have no barriers in practicing evidence-based healthcare. (10) 
 
Demographic Information 
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Q19 I am 
 Male (1) 
 Female (2) 
 
Q20 Race/Ethnicity:   
 White/Caucasian (1) 
 Black/African American (2) 
 Hispanic/Latino (3) 
 Asian (4) 
 Native American (5) 
 Pacific Islander (6) 
 Other (7) 
 
Q21 Age: ___ (will be free text)  
 
This concludes the survey. Thank you for your participation.   
 
Below is a link to a handout that summarizes the use of Sublingual nitroglycerin (SLNTG)  as 
included in the 2012 Guideline for the Diagnosis and Management of Patients with Stable 
Ischemic Heart Disease.      
 
The Nitroglycerin handout       (copy of handout below) 
 
Sincerely,      
 
Melinda Matthews, MSN, APRN, ANP,BC, DNP Student   
East Carolina University, College of Nursing 
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D2: The Nitroglycerin Handout as embedded in the DNP SLNTG Survey, downloadable to 
Survey Participants 
 
  
Sublingual Nitroglycerin:    
A Guide for Patient & 
Provider Instruction 
By 
Melinda Matthews, RN, MSN, ANP, BC, DNP-Student 
Based on the 2012 ACCF/AHA Guideline for Diagnosis 
and Management of Stable Ischemic Heart Disease.  
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THE BASICS 
♥ S: Stable Ischemic Heart Disease: predictable chest pain, appropriate for prescription of sublingual 
nitroglycerin (SLNTG). As is diagnosis of angina, coronary artery disease (CAD), post myocardial 
infarction (MI), post percutaneous coronary intervention (PCI/stents) and/or coronary artery bypass 
grafting (CABG) 
 
♥ L: Listen: To your patients – Ask at each visit if they are having chest pain and if they need a refill 
on their SLNTG.  Remind them each visit how to use the nitro. Including use of SLNTG as 
premedication for exercise-induced angina.  
 
♥ N: Nitrates: works to vasodilate the coronary arteries and increases blood flow to the heart 
muscle  eases chest pain.  
 
♥ I: Instructions for use: Sit down, place tablet under tongue, wait 5 minutes, can repeat x 2. If 
still having chest pain  Call 911. (Spray works the same, just spray on tongue, not under). 
Warn of possible (normal) side effects – hypotension, dizziness and/or headache. Should 
report if has syncope.  
 
♥ T: Take Caution: in use with hypertrophic obstructive cardiomyopathy. 
 
♥ R: Risk: Avoid with severe aortic stenosis. 
 
♥ O: Other meds? Ask if taking phosphodiesterase inhibitors, such as Viagra, Cialis or Levitra.  
Advise cannot use SLNTG within 24 hours of Viagra. Cannot use within 48 hrs with Cialis. 
Suitable time for use after Levitra has not been determined.  Remind them that is okay to use 
SLNTG even if wearing nitroglycerin patch.  
 
ADDITIONAL RESOURCES FOR MORE INFORMATION ON THE 2012 GUIDELINE 
FOR STABLE ISCHEMIC HEART DISEASE 
Below are articles and guidelines you may find helpful if interested in reading more about SIHD and use 
of SLNTG. 
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blandenship, J. C., Dallas, A. P., & ... Williams, S. V. 
(2012). 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and 
management of patients with stable ischemic heart disease: A report of the American College of 
Cardiology Foundation/American Heart Association task force on practice guidelines,. Journal 
of the American College of Cardiology, 60(24), e44 -e164. 
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blandenship, J. C., Dallas, A. P., & ... Williams, S. V. 
(2012). 2012 ACCF/AHA/ACPAATS/PCNA/SCAI/STS guideline for the diagnosis and 
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management of patients with stable ischemic heart disease: Executive Summary. Journal of the 
American College of Cardiology, 60, 2564-2603. Retrieved from http://content.onlinejacc.org 
Lewis, J. M., & Davis, L. L. (2013). Management of stable ischemic heart disease. The Journal of Nurse 
Practitioners, 9(10), 661-668. 
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Appendix E: IRB Approval Letters  
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Appendix F 
Table F1: Clinical Practice Questions (CPQ), Survey Question that Addresses the CPQ, and Statistical Test Used 
Survey 
Q# 
(SQ#):  
Question Statistical Test Used 
CPQ 1. Do NPs in NC practicing in primary care and specialty clinics report an understanding of the use of SLNTG for the self-
management of angina? 
 
   SQ#9 As a general rule, how likely are you to provide an initial prescription (RX) for 
sublingual nitroglycerin in the following conditions? 
 
 
Descriptive stats  
SQ#11 Scenario Question: seeking to see if NPs know to tell patients to premedicate for effort-
induced angina. 
Descriptive stats 
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Ms. Jones, a 56 year old white female, enjoys working in her garden. She finds after 
about 15 minutes of working at moderate pace, she develops chest pain (her typical 
symptoms of left chest pain that radiates to her jaw). She usually stops working in the 
garden and goes in the house, rests and after about 5 minutes, the pain resolves on its 
own. She is on metoprolol (a beta-blocker), Imdur (long-acting nitrate), Lisinopril 
(ACE-inhibitor) and Ranolazine (Ranexa) and has a prescription for sublingual 
nitroglycerin. She also has hypertension. Your recommendations include: (Select yes or 
no for each statement)   
 Yes (18) No (19) 
You inform her she is 
doing the right thing 
by going in the house 
and resting, as one 
has to be careful and 
not over do it with 
heart disease. (1) 
    
You consider 
increasing her Imdur 
and/or Ranexa (2) 
    
You advise her to 
take a sublingual 
nitroglycerin 5-10 
minutes before the 
planned activity 
(gardening) and see 
if that will allow her 
to work longer in her 
garden before 
developing chest 
pain, possibly up to 
30-40 minutes before 
    
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development of 
symptoms. (3) 
You advise her to 
immediately call 911 
with any chest pain. 
(4) 
    
 
 
SQ#12 Scenario Question: seeking if NPs know issues around the use of SLNTG and Viagra. 
Mr. Thompson is a 70 yo male with coronary artery disease, Erectile Dysfunction, and 
hypertension. He and his wife report being sexually intimate. His current medications 
include beta-blocker, ACE-inhibitor, Aspirin, statin and Ranolazine (Ranexa). He 
requests a prescription (RX) for both Viagra and Sublingual Nitroglycerin. What 
instructions MUST you provide?  (Select yes or no for each statement) 
 Yes (9) No (10) 
None, as he is not on a long-
acting nitrate, so use of 
phosphodiesterase inhibitors, 
such as Viagra is okay. (1) 
    
Advise him it is okay to have 
a prescription for Viagra, as 
he is not on a long-acting 
nitrate. But withhold the 
prescription for sublingual 
nitroglycerin. (2) 
    
Descriptive stats 
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Advise him it is okay to have 
prescription for both Viagra 
and sublingual nitroglycerin 
but caution him that he 
should not use the sublingual 
nitroglycerin  within 24 
hours of using the Viagra. (3) 
    
Suggest he should avoid 
having sex with his wife with 
his heart disease. (4) 
    
 
 
SQ#13 Scenario Question: seeking if NPs know correct dosing sequence for SLNTG based on the 
2012 Guideline for SIHD. 
Ms. Smith, a 68 year old white female with hypertension, diabetes, hyperlipidemia, 
stage 3 chronic kidney disease as well as coronary heart disease with previous history of 
myocardial infarction 2 years ago, and now status post myocardial infarction 3 days 
ago.  She did not get a stent at that time, but is being treated medically. She is on the 
usual medications, including aspirin, statin, Beta-Blocker, ACE-inhibitor and Ranexa. 
She is given a RX for sublingual nitroglycerin as well as Instructions for use, which 
should include:  (select yes or no for each statement) 
 Yes (10) No (11) 
Once she obtains the RX for 
sublingual nitroglycerin, be 
sure and transfer them 
directly to her pillbox that 
she keeps in her purse. (1) 
    
Remind her that the pills 
should be used daily whether 
she is having CP or not. (2) 
    
Descriptive stats 
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Instruct her to place a pill 
under her tongue if develops 
chest pain (CP) that does not 
resolve w/ rest after a few 
minutes. Instruct her to take 
1 tablet every 5 minutes (up 
to 3 tabs) and if still having 
CP with the 3rd one, she 
should call 911. (3) 
    
Advise her to remain 
standing while taking the 
sublingual nitroglycerin as it 
works better that way. (4) 
    
Stop the medication 
immediately if she 
experiences a headache or 
blurred vision, as this 
suggests an uncommon 
reaction to the medication. 
(5) 
    
 
 
SQ#14 Scenario Question: seeking if NPs know when to tell patients to replace their bottle of 
SLNTG. 
A patient should be instructed to replace their bottle of sublingual nitroglycerin: (select 
yes or no for each statement)    
 Yes (9) No (10) 
According to the expiration 
date on the side of the bottle 
(as long as the bottle has not 
been opened) (1) 
    
Descriptive stats 
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6-12 months after they have 
opened the bottle (2) 
    
Only after they have used all 
their pills, no matter how 
long they have had them. (3) 
    
 
 
SQ#15 What factors prevent you from prescribing sublingual nitroglycerin when clinically 
indicated? (select all that apply) 
 I am uncomfortable writing for this medication – afraid it will harm my patient. (1) 
 I have never written a prescription for sublingual nitroglycerin and do not plan to write 
one. (2) 
 My supervising physician does not believe patients who have had stents or coronary 
bypass surgery (CABG) need a prescription for sublingual nitroglycerin. (3) 
 I have no problems writing an initial or refill prescription for sublingual nitroglycerin. (4) 
 I have no problems refilling sublingual nitroglycerin once the initial prescription 
provided by a cardiology provider (5) 
 I do not provide prescription for sublingual nitroglycerin because if patient having chest 
pain, they should go to the emergency room for further evaluation. (6) 
 I do not write prescriptions in the practice where I work. (7) 
 
 
Descriptive stats 
 
CPQ 2. Do NPs report an understanding of contraindications for the use of SLNTG? 
 
SQ#9 As a general rule, how likely are you to provide an initial prescription (RX) for 
sublingual nitroglycerin in the following conditions? 
 Always (1) Very Likely (2) 
Very Unlikely 
(3) 
Never (4) 
Descriptive stats 
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Angina or chest 
pain (CP) (1) 
        
Coronary artery 
disease (CAD) 
(2) 
        
Status post 
myocardial 
infarction (S/p 
MI) (3) 
        
Status post 
percutaneous 
coronary 
intervention (s/p 
PCI) (4) 
        
Status post 
coronary artery 
bypass grafting 
(s/p CABG) (5) 
        
Hypertrophic 
obstructive 
cardiomyopathy 
(HOCM) (6) 
        
Severe aortic 
stenosis (AS) (7) 
        
 
 
SQ#12 Scenario Question: seeking if NPs know issues around the use of SLNTG and Viagra. 
Mr. Thompson is a 70 yo male with coronary artery disease, Erectile Dysfunction, and 
hypertension. He and his wife report being sexually intimate. His current medications 
include beta-blocker, ACE-inhibitor, Aspirin, statin and Ranolazine (Ranexa). He 
Descriptive stats 
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requests a prescription (RX) for both Viagra and Sublingual Nitroglycerin. What 
instructions MUST you provide?  (Select yes or no for each statement) 
 Yes (9) No (10) 
None, as he is not on a long-
acting nitrate, so use of 
phosphodiesterase inhibitors, 
such as Viagra is okay. (1) 
    
Advise him it is okay to have 
a prescription for Viagra, as 
he is not on a long-acting 
nitrate. But withhold the 
prescription for sublingual 
nitroglycerin. (2) 
    
Advise him it is okay to have 
prescription for both Viagra 
and sublingual nitroglycerin 
but caution him that he 
should not use the sublingual 
nitroglycerin  within 24 
hours of using the Viagra. (3) 
    
Suggest he should avoid 
having sex with his wife with 
his heart disease. (4) 
    
 
 
 
CPQ 3. Does the understanding and utilization of SLNTG in the SIHD patient differ among practice specialties? 
 
SQ#5 Practice type (cardiology vs. all others) Analysis of relationship 
between Practice Type and 
knowledge questions (SQ#s: 
11, 12, 13, and 14).  
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Please indicate the practice type where you spend the majority of your time as a Nurse 
Practitioner: 
 Primary Care Setting/Internal Medicine/Family Practice (1) 
 Nursing Home/Long-term Care Facility/assisted Living or Short-term Rehabilitation (2) 
 Retail Clinic (3) 
 Urgent or Intermediate Care (4) 
 Specialty Clinic: Cardiology (5) 
 Specialty Clinic: Nephrology (6) 
 Hospital (7) 
 Other (10) 
 I do not see patients with stable ischemic heart disease (or chest pain) (11) 
If I do not see patients with ... Is Selected, Then Skip To This concludes the survey. 
Thank you ... 
 
 
 
Chi Square for independence 
 
SQ#11 Scenario Question: seeking to see if NPs know to tell patients to premedicate for effort-
induced angina. 
Ms. Jones, a 56-year-old white female, enjoys working in her garden. She finds after 
about 15 minutes of working at moderate pace, she develops chest pain (her typical 
symptoms of left chest pain that radiates to her jaw). She usually stops working in the 
garden and goes in the house, rests and after about 5 minutes, the pain resolves on its 
own. She is on metoprolol (a beta-blocker), Imdur (long-acting nitrate), Lisinopril 
(ACE-inhibitor) and Ranolazine (Ranexa) and has a prescription for sublingual 
nitroglycerin. She also has hypertension. Your recommendations include: (Select yes or 
no for each statement)   
 Yes (18) No (19) 
You inform her she is doing 
the right thing by going in 
the house and resting, as one 
has to be careful and not 
    
Analysis of relationship 
between Practice Type and 
knowledge questions (SQ#s: 
11, 12, 13, and 14).  
 
Chi Square for independence 
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over do it with heart disease. 
(1) 
You consider increasing her 
Imdur and/or Ranexa (2) 
    
You advise her to take a 
sublingual nitroglycerin 5-10 
minutes before the planned 
activity (gardening) and see 
if that will allow her to work 
longer in her garden before 
developing chest pain, 
possibly up to 30-40 minutes 
before development of 
symptoms. (3) 
    
You advise her to 
immediately call 911 with 
any chest pain. (4) 
    
 
 
SQ#12 Scenario Question: seeking if NPs know issues around the use of SLNTG and Viagra. 
Mr. Thompson is a 70 yo male with coronary artery disease, Erectile Dysfunction, and 
hypertension. He and his wife report being sexually intimate. His current medications 
include beta-blocker, ACE-inhibitor, Aspirin, statin and Ranolazine (Ranexa). He 
requests a prescription (RX) for both Viagra and Sublingual Nitroglycerin. What 
instructions MUST you provide?  (Select yes or no for each statement) 
 Yes (9) No (10) 
None, as he is not on a long-
acting nitrate, so use of 
phosphodiesterase inhibitors, 
such as Viagra is okay. (1) 
    
Analysis of relationship 
between Practice Type  and 
knowledge questions (SQ#s: 
11, 12, 13, and 14).  
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Advise him it is okay to have 
a prescription for Viagra, as 
he is not on a long-acting 
nitrate. But withhold the 
prescription for sublingual 
nitroglycerin. (2) 
    
Advise him it is okay to have 
prescription for both Viagra 
and sublingual nitroglycerin 
but caution him that he 
should not use the sublingual 
nitroglycerin  within 24 
hours of using the Viagra. (3) 
    
Suggest he should avoid 
having sex with his wife with 
his heart disease. (4) 
    
 
 
SQ#13 Scenario Question: seeking if NPs know correct dosing sequence for SLNTG based on the 
2012 Guideline for SIHD. 
Ms. Smith, a 68 year old white female with hypertension, diabetes, hyperlipidemia, 
stage 3 chronic kidney disease as well as coronary heart disease with previous history of 
myocardial infarction 2 years ago, and now status post myocardial infarction 3 days 
ago.  She did not get a stent at that time, but is being treated medically. She is on the 
usual medications, including aspirin, statin, Beta-Blocker, ACE-inhibitor and Ranexa. 
She is given a RX for sublingual nitroglycerin as well as Instructions for use, which 
should include:  (select yes or no for each statement) 
 Yes (10) No (11) 
Once she obtains the RX for 
sublingual nitroglycerin, be 
sure and transfer them 
    
Analysis of relationship 
between Practice Type and 
knowledge questions SQ#s: 
11, 12, 13, and 14).  
 
Chi Square for independence 
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directly to her pillbox that 
she keeps in her purse. (1) 
Remind her that the pills 
should be used daily whether 
she is having CP or not. (2) 
    
Instruct her to place a pill 
under her tongue if develops 
chest pain (CP) that does not 
resolve w/ rest after a few 
minutes. Instruct her to take 
1 tablet every 5 minutes (up 
to 3 tabs) and if still having 
CP with the 3rd one, she 
should call 911. (3) 
    
Advise her to remain 
standing while taking the 
sublingual nitroglycerin as it 
works better that way. (4) 
    
Stop the medication 
immediately if she 
experiences a headache or 
blurred vision, as this 
suggests an uncommon 
reaction to the medication. 
(5) 
    
 
 
SQ#14 Scenario Question: seeking if NPs know when to tell patients to replace their bottle of 
SLNTG. 
Analysis of relationship 
between Practice Type and 
knowledge questions (SQ#s: 
11, 12, 13, and 14).  
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A patient should be instructed to replace their bottle of sublingual nitroglycerin: (select 
yes or no for each statement)    
 Yes (9) No (10) 
According to the expiration 
date on the side of the bottle 
(as long as the bottle has not 
been opened) (1) 
    
6-12 months after they have 
opened the bottle (2) 
    
Only after they have used all 
their pills, no matter how 
long they have had them. (3) 
    
 
 
 
Chi Square for independence 
 
Demographic type question 
SQ#1 What is your highest level of education in nursing? 
 Diploma RN (1) 
 ADN (2) 
 BSN (4) 
 BS (5) 
 MSN (6) 
 DNP (7) 
 PhD (8) 
 Other (Please comment): (9) ____________________ 
 
Descriptive stats 
SQ#2 What is your highest level of education as an Advanced Practice Registered Nurse 
(APRN):  
 Certificate (1) 
 Graduate (2) 
 
Descriptive stats 
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SQ#3 Q3 Please indicate the title(s) that best describes your current APRN role: 
 Acute Care Nurse Practitioner (ACNP) (1) 
 Adult Nurse Practitioner (ANP) (2) 
 Family Nurse Practitioner (FNP) (3) 
 Gerontology Nurse Practitioner (GNP) (4) 
 Adult/Gerontology Primary Care (AGPCP) (5) 
 Other (please comment): (7) ____________________ 
 
Descriptive stats 
SQ#4 Please indicate which region in North Carolina (NC) your primary NP practice is 
located: 
 Coastal Plains (Beaufort, Bertie, Bladen, Brunswick, Camden, Carteret, Chowan, 
Columbus, Craven, Cumberland, Currituck, Dare, Duplin, Edgecombe, Gates, Greene, 
Halifax, Harnett, Hertford, Hoke, Hyde, Johnston, Jones, Lenoir, Martin, Nash, New 
Hanover, Northampton, Onslow, Pamlico, Pasquotank, Pender, Perquimans, Pitt, 
Roberson, Sampson, Scotland, Tyrell, Washington, Wayne, Wilson) (1) 
 Piedmont (Alamance, Alexander, Anson, Cabarrus, Caswell, Catawba, Chatham, 
Cleveland, Davidson, Davie, Durham, Forsyth, Franklin, Gaston, Granville, Guilford, 
Iredell, Lee, Lincoln, Mecklenburg, Montgomery, Moore, Orange, Person, Randolph, 
Richmond, Rockingham, Rowan, Stanley, Surry, Union, Vance, Wake, Warren, Yadkin) 
(2) 
 Mountains (Alleghany, Ashe, Avery, Buncombe, Burke, Caldwell, Cherokee, Clay, 
Graham, Haywood, Henderson, Jackson, Macon, Madison, McDowell, Mitchell, Polk, 
Rutherford, Swain, Transylvania, Watauga, Wilkes, Yancey) (3) 
 
Descriptive stats 
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SQ#5 Please indicate the type of practice in which you are employed: 
 Primary Care Setting/Internal Medicine/Family Practice (1) 
 Nursing Home/Long-term Care Facility/assisted Living or Short-term Rehabilitation (2) 
 Retail Clinic (3) 
 Urgent or Intermediate Care (4) 
 Specialty Clinic: Cardiology (5) 
 Specialty Clinic: Nephrology (6) 
 Other: (7) ____________________ 
 I do not see patients with stable ischemic heart disease (or chest pain) (8) 
If I do not see patients with ... Is Selected, Then Skip To This concludes the survey. Thank 
you ... 
 
Descriptive stats 
SQ#6 How many years have you been in clinical practice in your current APRN role? __ (free 
text) 
 
Mean/standard deviation 
SQ#7 Do you have prescribing privileges? 
 Yes (9) 
 No (10) 
 
Descriptive stats 
SQ#8 In your day-to-day practice, how often do you see a patient with the diagnosis of: 
 Daily (1) Weekly (2) Monthly (3) 
Hardly ever 
(4) 
Never (5) 
Angina or chest 
pain (CP) (1) 
          
Coronary artery 
disease (CAD) 
(2) 
          
Status post 
myocardial 
          
Descriptive stats 
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infarction (S/p 
MI) (3) 
Status post 
percutaneous  
coronary 
intervention 
(s/p PCI) (4) 
          
Status post 
coronary artery 
bypass grafting 
(s/p CABG) (5) 
          
Hypertrophic 
obstructive 
cardiomyopathy 
(HOCM) (6) 
          
Severe aortic 
stenosis (AS) 
(7) 
          
 
 
SQ#10 Are you aware of the guidelines for diagnosis and management of patients with stable 
ischemic heart disease? 
 Yes (1) 
 No (2) 
 
Descriptive stats 
SQ#19 I am 
 Male (1) 
 Female (2) 
 
Descriptive stats 
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SQ#20 Race/Ethnicity:   
 White/Caucasian (1) 
 Black/African American (2) 
 Hispanic/Latino (3) 
 Asian (4) 
 Native American (5) 
 Pacific Islander (6) 
 Other (7) 
 
Descriptive stats 
SQ#21 Age: ___ (free text) Mean/standard deviation 
 
General question 
SQ#16 How often do you look up clinical guidelines for a specific problem/disease/ disorder? 
 Never (11) 
 Less than Once a Month (12) 
 Once a Month (13) 
 2-3 Times a Month (14) 
 Once a Week (15) 
 2-3 Times a Week (16) 
Daily (17) 
Descriptive stats 
SQ#17 Please indicate if you have access and if you use the following resources for reviewing 
clinical guidelines or medication information  (select all that apply): 
 I have access (1) I have used (2) 
Google/Yahoo/Bing (1)     
Google Scholar (2)     
UpToDate (3)     
National Guideline 
Clearinghouse (4) 
    
American Heart Association 
(5) 
    
Descriptive stats 
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Medscape (6)     
Lexicomp (7)     
Micromedex (8)     
Epocrates (9)     
I have access to a health 
science library at/through my 
practice - several resources 
available. (10) 
    
I usually also confer with my 
NP colleagues (11) 
    
I ask my supervising 
physician (12) 
    
 
 
SQ#18 The following are reasons (barriers) to why I may not consistently practice evidence-
based healthcare (select all that apply): 
 Lack of familiarity or awareness of available clinical guidelines. (1) 
 Not enough time to stay informed. (2) 
 Lack of access to guidelines. (3) 
 I do not typically agree with guidelines. (4) 
 Guidelines are too "cookbook". (5) 
 I find that the guidelines usually do not provide the expected outcomes. (6) 
 I try to use guidelines, but my patients are not compliant. (7) 
 I do not have time to review the information in guidelines with my patients. (8) 
 The practice with which I work does not endorse the use of clinical guidelines. (9) 
 I have no barriers in practicing evidence-based healthcare. (10) 
 
Descriptive stats 
Note. CPQ: clinical project question; SQ: survey question; NPs: nurse practitioners; NC: North Carolina; SLNTG: sublingual 
nitroglycerin; RX: prescription; SIHD: stable ischemic heart disease; DX: diagnosis; CP: chest pain;  
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Appendix G 
 
Checklist for Reporting Results of Internet E-Surveys (CHERRIES) Tools 
ITEM 
CATEGORY 
CHECKLIST ITEM  EXPLANATION 
 
Design 
Describe survey 
design 
p. 30 
 
Type of design – nonexperimental, cross-sectional, quantitative, descriptive 21-item survey; target 
pop – NPs in NC in primary care/internal medicine/family practice, nursing home/long-term 
care/assisted-living/short-term rehabilitation, retail clinics, urgent care/intermediate care clinics, 
cardiology, nephrology or other.  
 
 
IRB 
IRB approval 
p.33 
Yes - IRB approval obtained 
 
Informed consent 
p. 33 
Informed consent implied in the introduction of survey tool (if participates in survey, consent 
implied); participants were told length of time for survey (approximately 10-12 minutes to 
complete); data stored on password protected computer x 3 years. 
Data protection 
p. 33 
Password protected computer, Qualtrics ® program (password protected as well) 
 
 
Development 
& Pre-Testing 
Development & 
testing 
p. 31-33 
Described development of this 21-item survey tool developed for DNP capstone project. That 21-
item survey item was pilot tested, and face validity and content validity obtained.  
 
Recruitment 
Process & 
Description of 
the Sample 
Having Access 
Open survey vs. 
closed survey 
p. 34 
Considered “closed survey” – anonymous survey link sent only to NPs from NC BON e-mail 
listserv. Not “open” in the sense of participants visiting a particular open website.  
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to the 
Questionnaire. 
 
 
 
 
 
 
Contact mode NA – as this was not a web-based survey. Was sent directly via e-mail 
Advertising the 
survey 
NA – no pre-advertising was done for this survey.  
Survey 
Administration 
Web/email 
p. 34 
Survey was e-mail survey 
 
Context 
p. 30 
Participants were NPs in NC  in above practice areas.  
 
Mandatory/ 
Voluntary 
p. 34 
Voluntary participation 
 
 
Incentives 
p. 34 
No incentives were offered 
 
Time/date 
p. 34 
Survey administered on 2/17/15 with 2 additional reminders 2/24/15 and 3/3/15 
 
Randomization of 
items or 
questionnaires 
 
NA – items were not randomized.  
 
 
Adaptive questioning 
p.38 
Skip-logic function was used to allow those who do not see patients with stable ischemic heart 
disease (or chest pain) as looking at NPs caring for these type pts.  
 
# of items 
p. 31-34 
21 items on survey –  11 demographic type questions with 2 matrix questions (1 frequency of 
seeing patient type, 1 knowledge question), 4 scenarios (to look at knowledge) and 4 general 
questions re: barriers to prescribing SLNTG and use of clinical practice guidelines (CPG).  
 
# of screens (pages) 
 
3 screens when administered online (not mentioned in write up) 
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Completeness check 
p. 33 
The survey was previewed/practice multiple times during development. Was sent for pilot testing 
by fellow students/NP colleagues. There was not a “non-response” option given, many (all but 
age, gender and race/ethnicity) for forced responses.  
 
Review step 
 
Not able to go back and change answers.  Not mentioned in write up 
 
Response 
Rates 
p. 34 & 39 Given this was an e-mailed survey, and not a web-based survey – many of the descriptors listed 
under this checklist item are NA for emailed survey. Only the response rate was discussed. Sent 
out 2238 surveys, 226 were used for analysis.  
Preventing 
Multiple 
Entries from 
the Same 
Individual 
p. 34 Author acknowledges use of Qualtrics ® function to avoid ballot box stuffing and responses were 
anonymized.  
 
Analysis 
Handing of 
incompletes 
questionnaires 
p. 34 
Author did mentioned that analysis done on only the 226 completed surveys.  Incomplete or 
partial surveys were not used.  
 
 
Questionnaires 
submitted with an 
atypical timestamp 
NA – no mention of this.  
 
 
 
Statistical corrections 
p. 36 
Statistical testing consisted mainly of descriptive statistics, and chi-square.  
 
 
Source: Checklist for Reporting Results of internet E-Surveys (CHERRIES). (2004). Journal of Medical Internet Research, 6(3): e34.        
doi: 10.2196/jmir.6.3.e34 
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Appendix H 
 
Respondent Characteristics (n=226)   
Demographics n % 
Highest Education (nursing)  
   Diploma Registered Nurse (RN) 
   Associate’s Degree in Nursing (ADN) 
   Bachelors of Science in Nursing (BSN) 
   Bachelors of Science (BS) 
   Masters of Science in Nursing (MSN) 
   Doctor of Nursing Practice (DNP) 
   Doctor of Philosophy (PhD) 
   Other 
 
1  
2  
0 
- 
197 
16 
5  
5  
 
 
0.4 
0.9 
0 
- 
87.2 
7.1 
2.2 
2.2 
Highest Education (NP) – could choose more than one  
   Certification 
   Graduate 
 
45  
195 
 
 
19.9 
80.1 
Current Title/Role  
   Acute Care Nurse Practitioner (ACNP) 
   Adult NP (ANP) 
   Family NP (FNP) 
   Gerontology NP (GNP) 
   Adult/Gerontology Primary Care NP (AGPCNP) 
   Other 
 
5  
41 
158  
7  
14  
1  
 
 
2.2 
18.1 
69.9 
3.1 
6.2 
0.4 
Region in NC  
   Coastal Plains 
   Piedmont 
   Mountains  
 
68 
133 
25 
 
 
30.0 
58.6 
11.0 
 
Practice setting  
   Primary care/Internal Medicine/Family Practice  
   Nursing home/Long-Term Care/Assisted Living/Short-term 
rehabilitation 
   Retail Clinic 
   Urgent care/Intermediate Care  
   Cardiology 
   Nephrology 
   Other 
 
 
118  
22  
 
8  
11  
32  
7  
28  
 
 
52.2 
9.7 
 
3.5 
4.9 
14.2 
3.1 
12.4 
 
Experience (in years), M (SD) 9.65 years 
 
7.64 
Prescribing Privileges (yes) 225 
 
99.1 
Aware of SIHD guideline (yes)  137 60.6 
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Gender 
   Male 
   Female 
 
15 
211 
 1 missing 
 
 
6.6 
93.0 
0.4 
Race/Ethnicity 
   White/Caucasian 
   Black/African American 
   Hispanic/Latino 
   Asian 
   Native American 
   Pacific Islander 
   Other 
 
190  
20 
2  
3  
6  
- 
3  
 
 
83.7 
8.9 
.9 
1.3 
2.7 
- 
1.3 
Age (in years), M (SD) 47.10 years 10.3 
Note. NP: nurse practitioner; NC: North Carolina; M: mean; SD: standard deviation 
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Appendix I 
 
 
Note. CP: chest pain; CAD: coronary artery disease; s/p MI: status post myocardial infarction; 
CABG: coronary artery bypass grafting, HOCM: hypertrophic obstructive cardiomyopathy; AS: 
aortic stenosis  
 
Figure 1: Frequency Seen by Diagnosis in Clinic (n=226) 
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Note. CP: chest pain; CAD: coronary artery disease; s/p MI: status post myocardial infarction; 
CABG: coronary artery bypass grafting, HOCM: hypertrophic obstructive cardiomyopathy; AS: 
aortic stenosis.  
 
Figure I2: Percentage of NPs that report would likely (or not) give an initial prescription (as 
appropriate) for SLNTG (Question 9; n=226) 
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Figure I3: Percentage Correct per Scenario Question (Questions 11, 12, 13, 14, n=226) 
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Table I1: Percentage correct by NP Title and Practice Type: Summary Table  
 
 Question 11 Question 12 Question 13 Question 14 
   n % 
Correct 
n % 
Correct 
n % 
Correct 
n % 
Correct 
Acute Care Nurse Practitioner (ACNP) (1) 3 60.00 5 100.00% 5 100.00% 5 100.00% 
Adult Nurse Practitioner (ANP) (2) 18 43.90 32 78.05% 39 95.12% 39 95.12% 
Family Nurse Practitioner (FNP) (3) 51 32.28 123 77.85% 153 96.84% 153 96.84% 
Gerontology Nurse Practitioner (GNP) (4) 2 28.57 5 71.43% 7 100.00% 7 100.00% 
Adult/Gerontology Primary Care Nurse 
Practitioner (AGPCNP) (5) 
5 35.71 9 64.29% 14 100.00% 14 100.00% 
Other (7)   1 100.00 1 100.00% 1 100.00% 1 100.00% 
           
   Question 11 Question 12 Question 13 Question 14 
   n % 
Correct 
n % 
Correct 
n % 
Correct 
n % 
Correct 
Primary Care Setting/Internal 
Medicine/Family Practice (1) 
39 33.05 93 78.81% 114 96.61% 99 83.90% 
Nursing Home/Long-term Care 
Facility/assisted Living or Short-term 
Rehabilitation (2) 
8 36.36 16 72.73% 22 100.00% 19 86.36% 
Retail Clinic (3)  3 37.50 6 75.00% 8 100.00% 5 62.50% 
Urgent or Intermediate Care (4) 2 18.18 8 72.73% 11 100.00% 11 100.00% 
Specialty Clinic: Cardiology (5) 15 46.88 30 93.75% 30 93.75% 27 84.38% 
Specialty Clinic: Nephrology (6) 3 42.86 4 57.14% 7 100.00% 6 85.71% 
Other (10)  10 35.71 18 64.29% 27 96.43% 20 71.43% 
Table: I2: Percentage Correct of Scenario Questions Measuring Knowledge of the 2012 
SIHD Guideline  
Question Cardiac Specialty 
 
Non-Cardiac Specialty 
  
 % n % n p-value 
11_3 47% 15 34% 66 .64 
12_3 94% 30 75% 145 .03 
13_3 94% 30 97% 188 .57 
14_2 84% 27 82% 159 .99 
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Appendix J 
 
Table J1: Barriers for Writing SLNTG, Frequency Look Up Clinical Practice Guidelines 
(CPG), Access/Use of Resources to Look Up CPG; Barriers to Practicing Evidence Based 
Healthcare (Question 15, 16, 17, 18 Results)  
Questions (Q) n % 
Q15:Factors that prevent NP from RX SLNTG when 
appropriate 
   Uncomfortable 
   Never wrote one and do not plan to 
   Pts with CABG/PCI – should NOT get RX 
   No problems – initial or refill 
   No problems – refill 
   Believe all patients with CP should go to hospital 
   I do not write RX 
 
 
 
8 
14 
2 
142 
131 
17 
12 
 
 
3.5 
6.2 
0.9 
62.6 
57.7 
7.5 
5.3 
 
Q16: Frequency look up clinical practice guidelines  
   Never 
   Less than once monthly 
   Once a month 
   2-3 times a month 
   Once a week 
   2-3 times a week 
   Daily 
 
 
1 
31 
22 
37 
29 
56 
50 
 
 
0.4 
13.7 
9.7 
16.4 
12.8 
24.8 
22.1 
Q17:Access/Use of Following Resources  
   Google/Bing/Yahoo  
   Google Scholar  
   Up-to-Date  
   National Guideline Clearinghouse  
   American Heart Association  
   Medscape  
   Lexicomp  
   Micromedex  
   Epocrates  
   Health Science Library  
   NP Colleague  
   Ask supervising Physician  
 
n 
187 
76 
169 
97 
163 
161 
50 
56 
160 
80 
146 
190 
% 
82.7 
33.6 
74.8 
42.9 
72.1 
71.1 
22.1 
24.8 
70.8 
35.4 
64.6 
84.1 
n 
128 
55 
137 
66 
111 
123 
45 
50 
128 
70 
102 
137 
% 
56.6 
24.3 
60.6 
29.2 
49.1 
54.4 
19.9 
22.1 
56.6 
31.0 
45.1 
60.6 
Q18: Barriers to EBP with CPG 
   Lack of awareness 
   Not enough time to stay informed 
   Lack of access 
   Do not agree 
   Too cookbook 
 
48 
50 
12 
0 
12 
 
21.2 
22.1 
5.3 
0 
5.3 
NURSE PRACTITIONER USE OF SUBLINGUAL NITROGLYCERIN  109 
   CPG do not provide expected outcome 
   Patients not compliant 
   No time to review with patients   
   Practice does not endorse use of CPG 
   No barriers 
 
5 
53 
15 
3 
127 
2.2 
23.5 
6.6 
1.3 
60.6 
Note. SLNTG: sublingual nitroglycerin; NP: nurse practitioner; RX: prescription; CABG/PCI: 
coronary bypass grafting/percutaneous coronary intervention; EBP: evidence based practice 
 
Figure J1: Years of Experience and NP Who Report Having Asked Supervising Physician 
Regarding Clinical Practice Guidelines and/or Medication Information.  
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Appendix K 
AACN DNP Essentials 
Essential I: Scientific Underpinnings for Practice:  
 Evaluated current practice of nurse practitioners (NPs) in their use of sublingual 
nitroglycerin (SLNTG) and plan to provide additional education, through dissemination of 
my findings to enhance the quality of care provided to patients with stable ischemic heart 
disease (SIHD).  
 Explored many theories, but settled on the use of Diffusion of Innovation to undergird this 
project.  With the innovation being the use of SLNTG as described in the 2012 SIHD 
Guideline.  
 
Essential II: Organization and System Leadership for Quality Improvement and Systems 
Thinking: 
 Determined a clinical interest related to my current practice – topic in the care of cardiac 
patients - decided on the use of SLNTG in the SIHD patient.  
 Evaluated current literature on the topic – available literature primarily from patient 
perspective, therefore, gap in knowledge related to NP providers.  
 Having found no formal evaluation of NPs and their use of SLNTG in the SIHD patient, 
elected to begin inquiry into this clinical topic, in hopes of improving the quality of care to 
patients with SIHD. 
 Plan to disseminate findings, first in required submission of journal article, then other 
available venues – one-on-one interprofessional interactions with colleagues (precepting 
advanced practice nurses); presentation of information in poster presentation at conference 
as available.  
 
Essential III: Clinical Scholarship and Analytical Methods for Evidence-Based Practice: 
 Determined this student’s interest in evaluating NP knowledge, barriers and use of SLNTG 
in the SIHD patient.  
 Reviewed literature related to this subject. As above, no articles found on NPs knowledge 
of SLNTG in the SIHD patient.  
 Used information technology and review of survey research to develop tool (survey) to 
assess NP knowledge, barriers and current use of SLNTG in the SIHD patient.  
 Survey and this author’s findings are the initial stages in understanding this clinical issue.  
 This author obtained face and content validity for the new tool. Reliability / Factor analysis 
was felt to be beyond the scope of this course.  
 Utilized the 2012 ACCF/AHA Guideline for Diagnosis and Management of the Stable 
Ischemic Heart Disease Patient (aka, 2012 SIHD Guideline); reviewed the 2014 
ACC/AHA Focused Update on the Diagnosis and Management of the SIHD patient.  
 This author’s scholarly project paper and subsequent journal article submission will 
disseminate survey findings and areas for further educational opportunities.  
 
Essential IV: Information systems/Technology and patient Care Technology for the 
Improvement and Transformation of Health Care:  
 Various forms of technology used for this DNP project.  
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 Review of literature using Medline via PubMed, Cumulative Index to Nursing and Allied 
Health Literature (CINAHL), Cochrane Database of Systematic Review.  
 Used Qualtrics ® for the design and launching of survey to NPs in North Carolina (NC).  
 Used of Excel for the List serv from NC Board of Nursing – data file, had to convert from 
excel file to comma-separated values (csv) file.  
 Used of Excel for some of the statistical analysis of data from the survey.  
 Used the Statistical Package for Social Sciences (SPSS) version 22 program for additional 
statistical analysis for data from the survey.  
 Used PowerPoint for presentation of findings.  
 General and frequent use of Internet for access to Institutional Review Board (IRB) site; 
general searches; submission of journal article.  
 Frequent use of e-mail for communication between committee chair and members.  
 
Essential V: Health Care Policy for Advocacy in Health Care:  
 One goal of this project is that the information gathered will be used to improve the care of 
patients with SIHD.  
 Nurse practitioners will be educated related to the findings that will enhance their care they 
provide the patients with SIHD.  
 Improvement in the care, will hopefully minimize anginal episodes which in turn will 
improve quality of life for these patients, decrease utilization of healthcare resources (ED 
visits, office visits, PCI, etc.).  
 These are all goals of the Institute of Health’s Triple Aim.  
 
Essential VI: Interprofessional Collaboration for Improving Patient and Population 
Health Outcomes:  
 Collaborated with committee chair and members throughout the project process from 
formation of topic, survey development to analysis of results.  
 Collaborated with health science librarian related to literature review techniques.  
 Collaborated with IRB team during the initiation of the IRB application. 
 Collaborated with Qualtrics specialist at CON. 
 Collaborated with Statistician both at CON and privately (professional statistician).  
 Communicated with Dr. Robyn Gallagher (in Australia) author of two of the studies used 
as guide for my project through e-mail communication.  
 Collaborated with fellow NPs in development of the survey – peer reviewers, classmates, 
one-on-one responses from a few of the NPs who took the survey, and one individual NP 
who provider constructive feedback on the survey and nitroglycerin handout.  
 
Essential VII: Clinical Prevention and Population health for Improving the Nation’s 
Health:  
 Established through literature review that millions of American’s are affected by angina. 
Healthy people 2020 include five of its 24 objectives related to cardiovascular health and 
risk factor reduction – which includes improvement of quality of life.  
 Review of literature also suggests that often patients are uninformed in the use of SLNTG 
and have many deficits around the use of SLNTG.  
NURSE PRACTITIONER USE OF SUBLINGUAL NITROGLYCERIN  112 
 Elected to evaluate NP knowledge, barriers and use of SLNTG in the SIHD patient using 
the 2012 SIHD Guideline.  
 As above, one goal of this DNP project is to improve the care NPs are providing to the 
patients with SIHD to improve their quality of life through equipping them with a tool 
(SLNTG) that will provide a means for self-managing their angina, which in turn will 
lessen their use of healthcare resources.  
 
Essential VIII: Advanced Nursing Practice: 
 Utilized findings during research aspect of this scholarly project to enhance the care this 
author providers to her own patients in a busy outpatient cardiology clinic.  
 Anticipate the findings from the study, once shared will enhance the care many other NP 
providers provide to their patients with SIHD.  
 Developed a handout for NP providers to use to educate their patients about the use of 
SLNTG.  
 Additional educational opportunities to be provided through the dissemination of the 
information found during this descriptive clinical survey project.  
 
Source: AACN. (2006). The essentials of doctoral education for advance nursing practice. 
Washington, DC: American Association of Colleges of Nursing. 
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